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Abstract 
 
There is long-standing debate regarding whether or not schizophrenia and schizoaffective 
disorder represent a single condition or two distinct disorders. Despite diagnostic criteria that 
differentiates these illnesses, clinical practice relies heavily upon subjective methods to separate 
these symptomatically overlapping conditions. Cognitive functioning has represented one of the 
main parameters evaluated in an attempt to discriminate between schizophrenia and 
schizoaffective disorder unfortunately with contradictory results.  Further, these comparative 
studies have traditionally been limited to intellectual and cognitive functioning and have not 
captured other factors such as social cognition. The current research tested the hypothesis that 
these two conditions are cognitively distinguishable based on comprehensive and well-validated 
measures of neurocognition (processing speed, working memory, visual learning and memory, 
verbal learning and memory, reasoning and problem solving, and attention).  This study is also 
the first to compare these diagnostic groups on multiple measures of social cognition (emotion 
perception, theory of mind, and attribution bias). Research participants included outpatients with 
a diagnosis of schizophrenia (n = 70) and schizoaffective disorder (n = 46), as well as 
comparison participants (n = 146). Across the various neurocognitive domains, there were no 
significant differences between diagnostic groups, with both uniformly performing worse than 
the comparison group. Discriminant function analysis revealed that performance on cognitive 
measures classified comparison group participants with a high degree of accuracy (93.8%) but 
far less so for those with schizophrenia (51.7%) and schizoaffective disorder (7.7%), suggesting 
substantial overlap between diagnostic groups on cognitive functioning. In terms of social 
cognition, the schizophrenia group was impaired on emotion perception relative to the 
schizoaffective disorder and comparison groups. The schizophrenia group was also impaired on 
theory of mind relative to the comparison group. Discriminant function analysis showed that 
performance on social cognitive tasks classified comparison participants accurately (83.4%) but 
far less so for those with schizophrenia (55.8%) or schizoaffective disorder (3.3%). These 
findings indicate that these two disorders are cognitively homogeneous, which is congruent with 
the majority of the literature, and suggests that schizoaffective disorder is not a distinct entity but 
is a subtype of schizophrenia.  Implications for research and clinical practice are discussed.  
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Schizophrenia and Schizoaffective Disorder: One Condition or Two? 
 Schizophrenia and schizoaffective disorder are two diagnoses within the psychotic 
disorder spectrum. It has been long debated whether similar or differing pathophysiological 
processes underlie these conditions, and more broadly, whether these diagnoses represent a 
single disorder or two distinct disorders. In his nosological descriptions of psychiatric illness, 
Emil Kraepelin (1920) created an explicit dichotomy between schizophrenia (dementia praecox) 
and bipolar disorder (manic-depressive insanity) (Malaspina et al., 2013). The validity of 
Kraepelin’s taxonomy was challenged by Jacob Kasanin (1933), who introduced the term acute 
schizoaffective psychosis, when he described nine patients with good premorbid functioning who 
then developed a mixture of psychotic and affective symptoms with a full recovery after a few 
months. 
 While schizoaffective disorder was initially regarded as a subtype of schizophrenia in the 
first two editions of the Diagnostic and Statistical Manual (DSM; see Table 1), the most recent 
version of the DSM (American Psychiatric Association, APA, 2013) attempts to distinguish 
schizoaffective disorder from both schizophrenia and mood disorders (see Table 2). 
Nevertheless, there is much debate over the status of schizoaffective disorder as a specific 
diagnostic category, as it overlaps both schizophrenia and mood disorders.  Over the years 
schizoaffective disorder has been conceptualized as: 1) a subtype of schizophrenia, with 
prominent mood symptoms; 2) a subtype of mood disorders, with prominent symptoms of 
psychosis; 3) an independent diagnostic entity, distinct from both schizophrenia and mood 
disorders; 4) a comborbid condition in which the same person simultaneously has both 
schizophrenia and a mood disorder; or 5) a heterogeneous or mixed group, composed of both 
schizophrenia and mood disorders (see Cheniaux et al., 2008). Additionally, a spectrum model 
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posits that psychosis severity varies on a continuum with schizophrenia and mood disorders at 
opposite ends and schizoaffective disorder intermediate between the two (see Cheniaux et al., 
2008; Malhi, Green, Fagiolini, Peselow, & Kumari, 2008).  Yet still others recommend that the 
concept of schizoaffective disorder be completely removed from diagnostic classification 
systems (e.g., Kempf, Hussain, & Potash 2005; Lake & Hurwitz, 2006; 2007; 2008) as it has 
poor diagnostic reliability, low temporal stability, unclear clinical utility, and weak validity (see 
Malaspina et al., 2013). While its removal was initially considered for DSM-5, schizoaffective 
disorder was ultimately maintained in the absence of sufficient clinical and theoretical data 
justifying such an omission (Malaspina et al., 2013). 
Table 1          Table 2 
                      
The Diagnosis of Schizoaffective Disorder      DSM-5 Criteria: Schizoaffective Disorder  
in Prior DSM Editions   
 
A. An uninterrupted period of illness 
during which there is a major mood 
episode (major depressive or manic) 
concurrent with Criterion A of 
schizophrenia. 
B. Delusions or hallucinations for two 
or more weeks in the absence of a 
major mood episode (depressive or 
manic) during the lifetime duration 
of the illness.  
C. Symptoms that meet criteria for a 
major mood episode are present for 
the majority of the total duration of 
the active and residual portions of 
the illness. 
D. The disturbance is not attributable to 
the effects of a substance (e.g., a 
drug of abuse, a medication) or 
another medical condition 
 
 Year Schizoaffective Disorder Diagnosis  
DSM I 1952 Schizophrenic reaction, Schizo-
affective type  
DSM II 1968 Schizophrenia, Schizo-affective 
type, excited 
Schizophrenia, Schizo-affective 
type, depressed 
DSM III 1980 Schizo-affective Disorder 
No operational diagnostic criteria 
DSM III-
R 
1987 Schizoaffective Disorder 
–Bipolar Type 
–Depressive Type 
Introduces four diagnostic criteria 
DSM-IV 
 
1994 Mixed subtype of Bipolar Type 
added 
No change of diagnostic criteria 
DSM-IV-
TR 
2000 No change of diagnostic criteria 
DSM-5 2013 Requires the assessment of mood 
symptoms for the entire course of a 
psychotic illness, which differs 
from the criterion in DSM-IV, 
which required only an assessment 
of the current period of illness 
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The ongoing controversy surrounding schizoaffective disorder reflects a more general 
and long-standing issue with mental disorder classification systems. Although the DSM creates 
the impression of relatively precise and distinct diagnostic categories, the boundaries between 
clinical entities are only based upon phenomenological descriptions, which are largely derived 
from clinical interviews, patient self-report, and subjective data. This results in substantial 
heterogeneity within diagnostic categories and overlapping clinical features between them. 
Succinctly put, “disease heterogeneity is often guaranteed, rather than simplified, through our 
current (DSM) diagnostic system” (Braff, Freedman, Schork, & Gottesman, 2007, p. 22). For 
instance, studies have found no clear symptom boundaries between schizophrenia, 
schizoaffective disorder, and affective disorders (for review, see Chineaux et al., 2008; Jager, 
Haack, Becker, & Frasch, 2011), demonstrating that clinical presentation alone does not permit a 
reliable differentiation between disorders.  Given the confounding heterogeneity of symptom 
expression and the imprecision of clinical diagnostic phenotypes, an alternative or 
complimentary approach may be to develop a neurobiologically-based psychiatric classification 
system, as has been proposed by the National Institute of Mental Health (NIMH; see Cuthbert & 
Insel, 2010). 
 One way through which the neurobiological underpinnings of heterogeneous disorders 
can be understood is through the analysis of discrete and neurobiologically relevant 
endophenotypes. Endophenotypes are defined as “quantitative traits believed to be intermediate 
between disease phenotypes and the biological processes that underlie them” (Bearden & 
Freimer, 2006, p. 307). In other words, endophenotypes are seen as closer to genetic variation 
than are clinical symptoms of a disorder (Braff et al., 2007). Moreover, the endophenotype 
approach reduces the complexity of symptoms and multifaceted behaviours by using 
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neurobiologically informed quantitative measures (Braff et al., 2007) such as measures of 
cognitive functioning.  
Comparing Neurocognition between Schizophrenia and Schizoaffective Disorder 
The frequency, pervasiveness, and stability of cognitive impairment among persons with 
schizophrenia (Heinrichs, 2005) and its strong association with impaired quality of life and poor 
outcome (Lepage, Bodnar, & Bowie, 2014), have led investigators to posit endophenotypic 
models of the illness with neurobiologically based impairments in cognitive function as a core 
component (e.g., Gottesman & Gould, 2003; Gur et al., 2007). Indeed, there is substantial 
evidence that cognitive measures of sustained attention, verbal declarative memory, and working 
memory are valid endophenotypes in schizophrenia (Gur et al., 2007) and the Food and Drug 
Administration considers cognitive impairment in schizophrenia an effective treatment target 
(Braff, 2015). While cognitive impairment is common among other disorders, such as bipolar 
disorder, the magnitude of the impairment is generally greater in schizophrenia (for review, see 
Madre et al., 2016), suggesting that the neurobiological basis of schizophrenia and bipolar 
disorder may differ.  
Establishing similarities and differences in the neurocognitive endophenotype of 
schizophrenia and schizoaffective disorder may provide important insights for future genetic 
studies (Braff et al., 2007), and could improve conceptualizations about the common and distinct 
aspects of the pathophysiology and clinical boundaries of the two disorders. Moreover, 
neurocognitive test performance may be useful in organizing such heterogeneous conditions into 
more biologically homogeneous subgroups (Heinrichs, 2005). Developing categorical diagnoses 
that have a neurobiological component is also important for creating targeted treatments, 
including pharmacological and sensory/cognitive training interventions (Braff, 2015). 
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If found that there are substantial differences in the cognitive performance of persons 
with schizophrenia and schizoaffective disorder, then this may signify that these diagnostic 
categories map onto different neurobiological entities and are thus distinct conditions, lending 
support to the current diagnostic classification system. Moreover, this could also mean that 
cognitive functioning be included as part of diagnostic criteria and therefore assessing cognition 
may become a routine part of diagnostic practices. However, if neurocognitive patterns between 
these diagnostic groups are not distinguishable, then it could suggest that schizoaffective 
disorder is not a distinct entity, which has important implications for research and clinical 
practices. Thus, the primary purpose of the present study was to determine whether 
schizophrenia and schizoaffective disorder are distinct or similar conditions by examining the 
extent to which they share underlying cognitive deficits. Cognitive functioning has represented 
one of the main parameters evaluated in an attempt to discriminate between schizophrenia and 
schizoaffective disorders unfortunately with contradictory results. 
Studies Finding Superior Performance in Schizoaffective Disorder 
  Several studies have found that individuals with schizoaffective disorder perform better 
on some cognitive tasks than those with schizophrenia (see Table 3). In an early study by Maj 
and colleagues (1986), individuals with schizoaffective disorder, depressed type (n =16) showed 
a consistent pattern of performance on a comprehensive cognitive battery which, on average, fell 
midway between that of persons with schizophrenia (n = 20), who were the most impaired, and 
major depressive disorder (n = 16), who were the least impaired. All of the diagnostic groups 
were significantly more impaired than the comparison group (n = 20). The authors concluded 
that individuals with schizoaffective depression encompass a heterogeneous group of cognitive 
syndromes, some of which are related to major depression and some to schizophrenia. 
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Nonetheless, the differences between the schizoaffective depression group compared to those 
with major depression or schizophrenia were non-significant and therefore it is unclear whether 
schizoaffective disorder truly falls midway between schizophrenia and major depressive 
disorder. 
 These results, however, were further supported by research conducted among outpatients 
with schizoaffective disorder and schizophrenia subtypes.  Bornstein and colleagues (1990) 
found that the schizoaffective disorder (n =18) and paranoid schizophrenia (n = 28) groups 
tended to have fewer cognitive deficits, and on most variables, the performance of these groups 
was intermediate between the age-matched comparison group (n = 52) and non-paranoid 
schizophrenia group (n = 27). When total symptom severity, education, and average daily 
medication dosage were covaried, the number and magnitude of cognitive differences between 
the diagnostic subgroups was attenuated. It was concluded that many of the cognitive differences 
between these groups were related to medication levels or symptom severity and the authors 
emphasized the need to control for the effects of these variables in comparison of diagnostic 
groups. Nevertheless, even with the covariates, the non-paranoid schizophrenia group remained 
more cognitively impaired than the other diagnostic groups on a variety of measures, suggesting 
that psychotic disorders are cognitively heterogeneous.  
 Lindenmayer, Kay, and Van Praag (1989) examined the cognitive profiles of hospitalized 
individuals, matched for age and length of illness, with schizophrenia (n = 21) and 
schizoaffective disorder (n = 21). While the schizophrenia group was significantly more 
impaired on verbal encoding and egocentricity of thought, their performance was comparable to 
the schizoaffective disorder group on verbal intelligence, memory, attention, and organic 
integrity.  Despite this, the authors claimed that the schizophrenia group showed “consistently 
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greater cognitive abnormality” (p. 423). In terms of cognitive symptoms, the schizophrenia 
group was significantly impaired on abstract thinking, insight, stereotyped thinking, spontaneous 
communication, and thought disorganization. It was concluded that these results support the 
validity of schizoaffective disorder as separate from schizophrenia. However, this assertion is 
primarily based upon self-reported cognitive symptoms rather than performance on objective 
measures of cognitive function. This is problematic as individuals with psychotic disorders often 
lack awareness of their cognitive deficits, subsequently rending patient self-reports an unreliable 
index of neurocognitive functioning (see Burton, Harvey, Patterson, & Twamley, 2016).  
 Goldstein and colleagues (2005) compared Veterans Affairs male inpatients with a DSM-
III-R diagnosis of schizoaffective disorder (n = 20) to patients with paranoid (n = 20), 
undifferentiated (n = 29) and residual (n = 14) subtypes of schizophrenia on a number of 
measures of cognitive function. While the schizoaffective disorder and paranoid schizophrenia 
groups were neuropsychologically indistinguishable, both groups performed significantly better 
than the undifferentiated and residual subtype groups. Application of cluster analysis indicated 
that there were relative high percentages of schizoaffective and paranoid patients in a 
“neuropsychologically normal” cluster. The authors concluded that schizoaffective disorder and 
clinical subtypes of schizophrenia are cognitively heterogeneous. However, these findings are 
outdated as schizophrenia subtypes no longer exist due to poor validity, low reliability, and 
limited diagnostic stability (see Tandon et al., 2013).  
  More recent studies continue to note superior neurocognitive performance in those with 
schizoaffective disorder compared to persons with schizophrenia.  A pilot study (Stip et al., 
2005) compared individuals with DSM-IV schizoaffective disorder (N =13) to those with 
schizophrenia (N = 44) on multiple computerized measures of visuomotor skills.  The testing was 
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repeated after two years to assess for divergence in performance between the two groups (the 
groups were matched for symptom severity). Testing over time is important as the diagnosis of 
schizoaffective disorder is often temporally unstable. A significant divergence was found with 
schizoaffective individuals performing significantly better on tasks of basic visuo-spatial motor 
skills and explicit memory. The relatively low sample size in the schizoaffective disorder group, 
however, could have been a confounding factor in reaching these significant divergences (Stip et 
al., 2005). Based on these findings, the authors concluded that those with schizoaffective 
disorder might have more preserved cognition, which may provide them with extra ability to 
successfully participate in treatment and function in the community.  
 Another study compared the performance of inpatients with DSM-IV schizophrenia and 
schizoaffective disorder, as well as a comparison group (14 demographically matched 
participants in each group), on measures of verbal and visuospatial working memory (Gruber, 
Gruber, & Falkai, 2006). On the first verbal working memory task assessing articulatory 
rehearsal, the schizophrenia group was significantly more impaired than both the schizoaffective 
disorder group and comparison group, with large effect sizes. On the second verbal working 
memory task assessing non-articulatory maintenance of phonological information, the 
schizophrenia group performed significantly worse than the comparison group, with a medium 
effect size. While the authors stated that there was a “statistical trend” for reduced performance 
of the schizophrenia group compared to the schizoaffective group on this task, this difference 
was not statistically significant. The three groups did not differ significantly on the visuospatial 
rehearsal task or on the visuospatial pattern maintenance task. As such, Gruber and colleagues 
(2006) conclusion that “schizophrenic patients exhibited pronounced impairments of both verbal 
and visuospatial working memory” (p. 25) is misleading as the three groups did not differ 
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significantly on tasks of visuospatial working memory. Nevertheless, the finding of intact verbal 
working memory in the presence of impaired spatial working memory among individuals with 
schizoaffective disorder suggests that these patients may have preserved articulatory rehearsal. 
This may represent a neurocognitive endophenotype that differentiates schizophrenia and 
schizoaffective disorder; however, replication with a larger sample is required (Gruber et al., 
2006).  Taken together, these two studies (Gruber et al., 2006; Stip et al., 2005) only suggest that 
specific areas of cognition are more preserved in schizoaffective disorder compared to 
schizophrenia. 
 In contrast, a large scale study, using DSM-IV criteria, reported that schizophrenia 
outpatients (n = 103) were significantly more impaired in processing speed, executive 
functioning, verbal episodic memory, and working memory measures relative to a group of 
schizoaffective disorder outpatients (n = 48) and a comparison group (n = 72), with moderate to 
large effect sizes (Heinrichs, Ammari, McDermid Vaz & Miles, 2008). Despite finding a relative 
impairment among the schizophrenia group on all cognitive measures, group differences in 
cognitive performance were of insufficient magnitude to predict a diagnosis of either 
schizophrenia or schizoaffective disorder. In fact, approximately two-thirds of patients with 
schizoaffective disorder were misclassified as having a diagnosis of schizophrenia based on the 
full set of cognitive predictors. Overall, this study found severe average cognitive impairment 
among participants diagnosed with schizophrenia, but very extensive overlap with the 
schizoaffective group, suggesting that these disorders may exist on a continuum.  
 Torniainen and colleagues (2012) compared cognitive functioning between population-
based familial samples of patients with DSM-IV schizophrenia (n = 218) and schizoaffective 
disorder (n = 62) derived from nationwide healthcare registers in Finland, as well as a 
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population-based comparison group (n = 123). While the comparison group significantly 
outperformed both diagnostic groups on all neuropsychological measures, the schizoaffective 
disorder group performed significantly better than the schizophrenia group on measures of verbal 
ability, processing speed, visual working memory, and verbal memory, with effect sizes ranging 
between small and medium. The two diagnostic groups did not differ significantly on tasks that 
assessed cognitive shifting, attention, and verbal working memory. Similar to previous research 
findings (e.g., Heinrichs et al., 2008), the effect sizes were not large enough to differentiate the 
diagnostic groups based on cognitive functioning because the distributions overlapped.  
 Importantly, after controlling for clinical characteristics (negative symptoms, positive 
symptoms, dose of antipsychotics, and age at onset) all significant differences in cognitive 
performance between the diagnostic groups disappeared (Torniainen et al., 2012). Thus, in 
accordance with some earlier studies (e.g., Bornstein et al., 1990), the difference in cognitive 
functions between these diagnostic groups was explained mostly by differences in the severity of 
negative symptoms, not by differences in mood symptoms or by some inherent difference 
between the two disorders. Overall, Torniainen and colleagues (2012) concluded that individuals 
with schizoaffective disorder have severe cognitive impairments, but that these tend to be milder 
than schizophrenia.  
 It is important to consider the argument that clinical characteristics should not have been 
covaried. For instance, if greater negative symptom severity is an intrinsic part of schizophrenia, 
the covarying of symptom level may artificially diminish the differences between diagnostic 
groups. When pre-existing groups are studied, observed differences may reflect some 
meaningful, substantive difference that is attributable to group membership. In this case, because 
symptoms are so intimately related to diagnosis, removal of variance in cognitive ability 
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associated with symptoms (i.e., covarying symptoms) would remove considerable variance in 
cognitive ability associated with diagnosis. Thus, despite this common practice of covarying, 
attempts to “control” for such differences by covarying have been deemed inappropriate with 
pre-existing groups (see Miller & Chapman, 2001). Moreover, covarying does not actually 
control for group differences, rather is intended to reduce variability of scores in groups that vary 
randomly (Miller & Chapman, 2001).  
 Hill and colleagues (2013) recently found that schizoaffective probands (N = 165) were 
significantly less neuropsychologically impaired than schizophrenia probands (N = 293) but were 
more impaired than psychotic bipolar probands (N = 227), suggesting that there is a continuum 
of cognitive deficits in psychotic disorders in which schizophrenia anchors one end (with the 
most severe deficits) and bipolar disorder anchors the other end (with significant but more 
modest deficits), with schizoaffective disorder falling intermediate between the two.  In contrast, 
another study found that those with schizoaffective disorder (N = 129) demonstrated significantly 
greater post-onset cognitive decline compared to individuals with bipolar disorder with 
psychotic features (N = 269), schizophrenia with no history of major affective episodes (N = 
371), and schizophrenia with a superimposed mood syndrome (N = 224),  such that those with 
schizophrenia exhibited levels of decline intermediate to bipolar disorder with psychosis and 
schizoaffective disorder, even after differences in demographic characteristics and lifetime 
symptomatology were covaried (DeRosse et al., 2013). To date this is the only study to find that 
those with schizoaffective disorder had more severe cognitive impairments than schizophrenia.  
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Table 3  
Studies Finding Significant Neurocognitive Differences between Schizoaffective Disorder and 
Schizophrenia  
 
References Population Measures Main Findings 
  
Maj et al., 1986 SZ = 20,  
SA-D = 7,  
MDD = 16, 
CG = 20 
 
LNNB  SZ < SA-D < MDD < CG 
(differences between SA-D 
and MDD and between SA-
D and SZ not statistically 
significant) 
 
Lindemayer et 
al., 1989 
SZ =21,  
SA = 21  
 
 
Egocentricity of Thought 
Test, MFD, MOT, 
PANSS cognitive 
symptoms, Quick Test of 
Verbal Intelligence, Span 
of Attention Test 
SZ < SA 
(SZ = SA for IQ, memory, 
attention and organic 
integrity)  
 
 
 
Bornstein et al., 
1990 
SZ-P = 28,  
SZ-U = 27, 
SA = 18, 
CG = 52 
Halstead-Reitan Battery, 
VCAT, WAIS-R, WCST, 
WMS-R  
 
SZ-UD < SA = SZ-P < CG 
(when medication 
level, total symptoms, and 
education were covaried, the 
magnitude and number of 
differences declined) 
 
Goldstein et al., 
2005 
SZ-P = 20, 
SZ-U = 29, 
SZ-R = 14, 
SA = 20  
 
HCT, HTPT, TMT-B, 
WAIS-R, WCST 
SZ-U = SZ-R < SA = SZ-P  
Stip et al., 2005 SZ = 44,  
SA = 13 
MST, PAL, Reaction 
Time Test, SOC 
 
SZ ≤ SA  
Gruber et al., 
2006 
SZ = 14,  
SA = 14,  
CG = 14 
Verbal and visuospatial 
Sternberg item-
recognition tasks 
 
SZ < SA = CG 
Heinrichs et al., 
2008 
SZ = 103,  
SA = 48,  
CG = 72 
 
CVLT, WAIS-III  
 
SZ < SA < CG 
(differences insufficient to 
separate diagnostic groups) 
Torniainen et al., 
2012 
SZ = 218, 
SA = 62,  
CG = 123 
CVLT, TMT-A&B, 
WAIS-R, WMS-R 
SZ < SA < CG 
(SZ = SA on TMT-A, digit 
span and visual span 
forward. After adjusting for 
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clinical features, all 
significant differences 
in cognitive performance 
between the diagnostic 
groups disappeared).   
 
Hill et al., 2013 SZ = 293,  
P-BD = 227, 
SA = 165,  
CG = 295 
 
BACS SZ < SA < P-BD < CG 
DeRosse et al., 
2013 
SZ(-) = 371, 
SZ(+) = 224,  
SA = 129,  
P-BD = 269 
Animal Naming, CVLT, 
COWAT, TMT-A&B, 
WAIS-R Digit Span, 
WRAT 
 
SA < SZ(-) = SZ(+) < P-BD 
Note. SA, schizoaffective disorder; SA-D, schizoaffective disorder, depressive episode; SZ, schizophrenia; SZ-P, 
schizophrenia paranoid; SZ-U, schizophrenia undifferentiated; SZ-R, schizophrenia residual; SZ(-), schizophrenia 
with no history of mood syndrome; SZ(+), schizophrenia with a superimposed mood syndrome; MDD, major 
depressive disorder; P-BD, psychotic bipolar disorder; CG, comparison group. BACS, Brief Assessment of 
Cognition in Schizophrenia; COWAT, Controlled Oral Word Association Test; CVLT, California Verbal Learning 
Test; HCT, Halstead Category Test; HTPT, Halstead Tactual Performance Test; LNNB, Luria-Nebraska 
Neuropsychological Battery; MFD; Memory for Designs Test of organic impairment; MOT, Memory Organization 
Test of verbal encoding; MST, Motor Screening Task; PAL, Paired Associates Learning task; SOC, Stockings of 
Cambridge items; TMT, Trail Making Test; VCAT, Verbal Concept Attainment Test;  WAIS-III, Wechsler Adult 
Intelligence Scale, Third Edition; WAIS-R, Wechsler Adult Intelligence Scale Revised; WCST, Wisconsin Card 
Sorting Test; WMS-R, Wechsler Memory Scale Revised; WRAT, Wide Range Achievement Test. (=) no significant 
differences; (<) greater cognitive functioning. 
Studies Finding Equivalent Performance in Schizoaffective Disorder 
 In contrast to the findings reported by Maj and colleagues (1986), Moses (1984) found 
that the LNNB failed to distinguish individuals with a DSM-III diagnosis of schizophrenia from 
those with schizoaffective disorder. Since that time, several other studies have found that 
individuals with schizoaffective disorder do not differ significantly from individuals with 
schizophrenia across several cognitive domains (e.g., Beatty, Jocic, Monson, & Staton, 1993; 
Manschreck, Maher, Beaudette, & Redmond, 1997; Miller, Swanson-Green, Moses, & 
Faustman, 1996; see Table 4).  
 In a study of 107 stabilized adult outpatients with their first-episode of schizophrenia, 
schizoaffective or schizophreniform psychosis, no significant differences were found between 
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diagnostic groups on standardized measures of intellect, memory, attention, and executive 
functioning (Townsend, Malla, & Norman, 2001).  There are a number of limitations to this 
study acknowledged by the authors, including the absence of a comparison group, the lack of 
control over potential demographic differences between their sample and normative samples, as 
well as differences between normative samples themselves, and the fact that this was a primarily 
male sample (Townsend et al., 2001). Moreover, the non-significant differences found between 
groups may be due to the small sample sizes in subgroups. 
  In a naturalistic study comparing measures of executive functioning among community-
dwelling individuals with RDC diagnosed schizophrenia (N = 34) and schizoaffective disorder 
(N = 23), as well as a comparison group (N = 30), Gooding and Tallent (2002) found that while 
both diagnostic groups exhibited executive dysfunction and performed significantly worse than 
the comparison group, the two diagnostic groups did not differ significantly from one another, 
suggesting that the two disorders share similar cognitive impairments.  The authors noted that 
these findings are consistent with several alternative conceptualizations of schizoaffective 
disorder and that it remains unclear whether schizoaffective disorder is a variant of 
schizophrenia, a hybrid disorder or a heterogenous condition. 
 Savage and colleagues (Savage, Jackson, & Sourathathone, 2003) found mild to moderate 
impairments on brief measures of memory, construction, concept formation, response set 
maintenance, psychomotor speed, and visual speed of information processing for outpatients 
with DSM-IV diagnosis of paranoid schizophrenia (n = 20), undifferentiated schizophrenia (n = 
21), and schizoaffective disorder (n = 20). The groups did not differ significantly from one other 
except on a task of abstract reasoning and psychomotor speed, in which those with 
schizoaffective disorder and paranoid schizophrenia performed significantly better than those 
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with undifferentiated schizophrenia (Savage et al., 2003). This study is limited by the lack of a 
comparison group, the small sample size in subgroups, and the use of a primarily male sample. 
 In a large scale study, 199 adults with DSM-IV diagnosed schizophrenia were compared 
to 73 individuals with schizoaffective disorder on measures of executive function, verbal and 
nonverbal memory, and processing speed with gender used as a covariate (Fiszdon, Richardson, 
Greig, & Bell, 2007). Consistent with the majority of previous findings, the two diagnostic 
groups did not differ significantly in their performance on the neurocognitive measures and 
results do not support a taxanomic distinction between the two disorders. The generalizability of 
these findings, however, may be limited by the fact that the majority of participants were 
veterans.  
 In a study of youth with DSM-IV diagnosis of schizophrenia (n = 79) and schizoaffective 
disorder (n = 40), Hooper and colleagues (2010) found that the groups did not differ significantly 
on intellect or any neuropsychological domains, such as fine-motor skills, attention, working 
memory, problem-solving efficiency, and inhibitory control.  The results were relatively 
unchanged even after age and socioeconomic status were covaried. An earlier study with children 
and adolescents also found no significant differences between those with schizophrenia and 
schizoaffective disorder on tasks of verbal memory but that both diagnostic groups performed 
worse than the comparison group after adjusting for differences in estimated premorbid 
intelligence (Roofeh et al., 2006).  
 Most recently, a large scale study of outpatients with schizophrenia (n = 188), 
schizoaffective disorder (n = 63), and a comparison group (n = 268) were assessed for goal 
maintenance in working memory, relational encoding and retrieval in episodic memory, and 
visual integration using the Cognitive Neuroscience Test Reliability and Clinical Applications 
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for Schizophrenia (Owoso et al., 2013). Across these three cognitive domains, no significant 
differences between diagnostic groups were found, with both groups uniformly performing 
worse than the comparison group (Owoso et al., 2013).  
 Other studies continue to find no significant neurocognitive differences between 
individuals diagnosed with schizophrenia and schizoaffective disorder (e.g., Pinna et el., 2014). 
Additionally, several of these studies have included a mood disorders group in an attempt to 
determine whether schizoaffective disorder exists on a continuum between schizophrenia and 
mood disorders. Based on a continuum model, it is anticipated that cognitive impairment will 
increase in severity from mood disorders to schizoaffective disorder to schizophrenia. 
 Silverstein, McDonald, and Meltzer (1988) found that inpatients with RDC 
schizoaffective disorder (n = 26), schizophrenia (n = 44), and major depression (n = 34) showed 
comparable impairments on the majority of neuropsychological variables. Overall, the results 
question the role of neuropsychological processes in discriminating psychiatric conditions and 
suggest that schizoaffective disorder may be no more distinct neuropsychologically than other 
psychiatric disorders. In contrast, Evans and colleagues (1999) found that the overall 
performance on a neuropsychological test battery was significantly more impaired among those 
with schizophrenia (n = 154) and schizoaffective disorder (n = 29) compared to patients with a 
non-psychotic mood disorder (n = 27), but that the two psychotic disorder groups did not differ 
significantly. These findings remained unchanged even when reanalyzed among age, gender, and 
education matched subsamples of the three diagnostic groups. Moreover, on the basis of 
discriminant function analysis, individuals in the schizoaffective disorder group were more likely 
to be classified as having schizophrenia than a mood disorder (Evans et al., 1999). These 
findings suggest that schizoaffective disorder is a variant of schizophrenia.  
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 A study of individuals with schizoaffective disorder (n = 345), schizophrenia (n = 270), 
affective disorder (n = 50), and unspecified functional psychosis (n = 42) found that after 
adjustment for ethnic group and social class, the four groups did not differ on a proxy measure of 
premorbid intelligence or on measures of visual conceptual and visuomotor tracking, suggesting 
a degree of cognitive homogeneity among these disorders (Gilvarry, Barber, Van Os, & Murray, 
2001). Similarly, Glahn and colleagues (2006) found that on backward digit span, a putative 
measure of verbal working memory, those in the schizophrenia (n = 15), schizoaffective 
disorder, depressive type (n = 15), bipolar disorder with psychotic features (n = 11) and non-
psychotic bipolar patients (n = 15) groups all performed significantly worse than the comparison 
group; however, the diagnostic groups’ performance were comparable to each other.  As such, 
the authors concluded that it may be an appropriate endophenotypic marker that cuts across 
diagnostic categories. In contrast, only patients with a lifetime history of psychotic features, 
regardless of diagnosis, were impaired on spatial delayed response task. 
 Another study (Szoke et al., 2008) compared performances on two tasks of executive 
functioning (Wisconsin Card Sorting Task, WCST and Trail Making Task, TMT) among DSM-
IV individuals with schizoaffective disorder (n = 26), schizophrenia (n = 48), bipolar disorder 
with psychosis (n = 52), bipolar disorder without psychosis (n = 40), as well as a comparison 
group (n = 48).  While the four diagnostic groups performed significantly worse than the 
comparison group on these two measures, the number of perseverative errors on the WCST was 
highest in the schizophrenia group and gradually decreased in the schizoaffective, bipolar with 
psychosis, and bipolar without psychosis groups. However, it is important to note that the only 
significant differences between the four diagnostic groups occurred between the schizophrenia 
group and the two bipolar disorder groups.  In other words, the schizoaffective disorder group 
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did not differ significantly from the other three diagnostic groups. On the TMT, the 
schizophrenia and schizoaffective disorder groups obtained relatively similar scores, as did the 
two bipolar disorder groups; however, the differences between the four diagnostic groups were 
not significant. The authors concluded that the pattern of results suggest that individuals with 
schizoaffective disorder resemble those with schizophrenia for certain cognitive deficits, whereas 
for other cognitive deficits there is a continuum of severity. Thus, different conceptual views 
about schizoaffective disorder should be seen as complementary, rather than mutually exclusive. 
 In a longitudinal, epidemiological study comparing neurocognitive performance profiles 
of first-admission psychotic patients with schizophrenia (n = 94), schizoaffective disorder (n = 
15), psychotic bipolar I disorder (n = 78), and psychotic major depression (n = 48), the 
schizophrenia group was more impaired than the other groups on all cognitive domains 
(Reichenberg et al., 2009). Nevertheless, the four diagnostic group’s cognitive profiles varied 
only minimally and were characterized by common relative deficits in memory, attention and 
processing speed, and executive functions (Reichenberg et al., 2009). Similarly, another study 
comparing acutely ill patients with schizoaffective disorder (n = 26), schizophrenia (n = 45), and 
bipolar disorder (n = 51), as well as a comparison group (n = 65), found that all three diagnostic 
groups performed significantly more poorly than the comparison group on global measures of 
memory and executive functioning, but that there were no significant differences between the 
diagnostic groups (Amann et al., 2012).  
 While all of these studies found that individuals with a diagnosis of schizophrenia or 
schizoaffective disorder share similar neuropsychological deficits, these studies failed to find 
support for the idea that cognitive impairment increases in severity from mood disorder to 
schizoaffective disorder to schizophrenia (with the exception of the aforementioned study by Hill 
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et al., 2013). Thus, most studies have found no clear evidence for a continuum model of 
cognitive impairment.  
Table 4 
Studies Finding No Significant Neurocognitive Differences between Schizoaffective Disorder and 
Schizophrenia   
 
References Population Measures Main Findings  
 
Moses et al., 
1984 
 
SZ = 85, 
SA = 21 
LNNB SA =SZ 
Silverstein et al., 
1988 
SZ = 44,  
SA = 26,  
MDD = 34 
LNNB  SA = SZ = MDD  
(SA < SZ = MDD for 
sensorimotor and SA = 
MDD < SZ for tactile 
function) 
 
Beatty et al., 
1993 
SZ = 13,  
SA = 13, 
CG = 20 
Category fluency, 
Design fluency, FAS,  
SECISM, WAIS-
R(digit span), WCST 
 
SA = SZ < CG  
(SZ more rapid 
forgetting) 
Miller et al., 
1996 
SZ = 26,  
SA-M = 9,  
SA-D = 17   
RAVLT, BVRT, 
LNNB, WAIS-R 
 
SA = SZ 
Manschreck et 
al., 1997 
SZ = 19,  
SA = 19, 
UD = 19,  
CG = 19 
 
 
Miller–Selfridge Task 
 
SA = SZ < UD = CG 
Evans et al., 
1999 
SZ = 154,  
SA = 29,  
NP-MD = 27  
ASTVS, BCT, CVLT, 
DVT, FMT, FTT, 
SMT, TMT, TPT, 
TWV, WAIS, WCST 
 
SA = SZ < NP-MD 
Townsend et al., 
2001 
SZ = 83,  
SA = 19 
 
CPT, PASAT, SCWT, 
TMT-A&B, WAIS-III, 
WCST, WMS-III 
 
SA = SZ 
Gilvarry et al., 
2001 
SZ = 270,  
SA = 345,  
MD = 50,  
UFP = 42 
TMT-A&B SA = SZ = MD = UFP 
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Gooding & 
Tallent, 2002 
SZ = 34,  
SA = 23,  
CG = 30 
  
SWM, WCST SA = SZ < CG 
Savage et al., 
2003 
SZ-P = 20,   
SZ-U = 21,  
SA = 20  
ASRT, Cognistat, 
COWAT, SDMT, 
TMT-A&B, WAIS-R 
SZ-P = SZ-U = SA 
(SZ-U < SA = SZ-P 
for similarities and 
TMT-A) 
 
Glahn et al., 
2006 
SZ = 5,  
SA = 15,   
P-BD = 11,  
NP-BD = 15,  
CG = 32  
SDRT, WAIS Backward digit span: 
BD = SZ = SA < CG 
Hx. of psychosis in 
spatial delayed 
response task: SA = 
SZ = P-BD = NP-BD 
 
Roofeh et al., 
2006 
SZ = 37, 
SA = 20,  
CG = 60  
 
CVLT SA = SZ < CG 
Fiszdon et al., 
2007 
SA = 73,  
SZ = 199 
 
HVLT-R, TMT,  
WAIS-III, WCST 
 
SA = SZ 
Szoke et al., 
2008  
SZ = 48,  
SA = 26,  
P-BD = 52,  
NP-BD = 40,  
CG = 48 
WCST, WMS-R  WCST: SZ < SA <P-
BD < NP-BD < CG 
TMT: SA = SZ 
Reichenberg et 
al., 2009 
SZ = 94,  
SA = 15,  
BD = 78,  
UD = 48 
FRT, FTT, LFSRT, 
SCWT, TMT-A&B, 
WAIS-R, WMS-R 
 
SZ < SA = BD = UD 
(SZ performed the 
worst but difference 
not significant 
compared to SA) 
  
Hooper et al., 
2010 
SZ = 79,  
SA = 40 
COWAT, CPT, FTT, 
HVLT, RFFT, VSWM, 
WRAML, WAIS, 
WCST, WRAT, WJ-III 
SA = SZ  
(SZ < SA in spelling) 
Amann et al., 
2012 
SZ = 45,  
SA-M = 26,  
BD-M = 51,  
CG = 65 
 
BADS, WMS SZ = SA-M = BD-M < 
CG 
Owoso et al., 
2013 
SZ = 188,  
SA = 63, 
CNTRACS (DPX, 
JOVI, RISE) 
SA = SZ < CG 
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CG = 268  
 
Pinna et al., 
2014 
SZ = 44, SA = 66 BACS, MMSE SA = SZ 
Note. SA, schizoaffective disorder; SA-M, schizoaffective disorder, manic episode; SA-D, schizoaffective disorder, 
depressive episode; SZ, schizophrenia; SZ-P, schizophrenia paranoid; SZ-U, schizophrenia undifferentiated; MDD, 
major depressive disorder; MD, mood disorder; NP-MD, non-psychotic mood disorder; BD, bipolar disorder; NP-
BD, non-psychotic bipolar disorder; P-BD, psychotic bipolar disorder; BD-M, bipolar disorder, manic episode; UD, 
unipolar depression; UFP = unspecified functional psychosis; CG, comparison group. ASRT, Anomalous Sentences 
Repetition Test; ASTVS, Aphasia Screening Test Verbal Score; BACS, Brief Assessment of Cognition in 
Schizophrenia; BADS, Behavioural Assessment of the Dysexecutive Syndrome; BCT, Booklet Category Test; 
BVRT, Benton Visual Retention Test; CNTRACS, Cognitive Neuroscience Test Reliability and Clinical 
Applications for Schizophrenia; COWAT, Controlled Oral Word Association Test; CPT, Continuous Performance 
Test; CVLT, California Verbal Learning Test; DPX, Dot Probe Expectancy; DVT, Digit Vigilance Test; FRT, Facial 
Recognition Test; FMT, Figure Memory Test; FTT, Finger Tapping Test; HVLT, Hopkins Verbal Learning Test; 
HVLT-R, Hopkins Verbal Learning Test, Revised; JOVI, Jittered Orientation Visual Integration; LNNB, Luria-
Nebraska Neuropsychological Battery; LFSRT, Letter Fluency and Sentence Repetition Test; MMSE, Mini Mental 
State Examination; PASAT, Paced Auditory Serial Addition Test; RAVLT, Rey Auditory Verbal Learning Test; 
RISE, Relational and Item-Specific Encoding; RFFT, Ruff Figural Fluency Test; SCWT, Stroop Colour-Word 
Interference Test; SDRT, Spatial Delayed Response Task; SDMT, Symbol Digit Modalities Test; SECIMS, 
Screening Examination for Cognitive Impairments in Multiple Sclerosis; SMT, Story Memory Test; SWM, Spatial 
Working Memory; TMT, Trail Making Test; TPT, Tactual Performance Test; TWV, Thurstone Written Fluency; 
VSWM, Visuospatial Working Memory; WAIS, Wechsler Adult Intelligence Scale; WAIS-R, Wechsler Adult 
Intelligence Scale, Revised; WAIS-III, Wechsler Adult Intelligence Scale, Third Edition; WCST, Wisconsin Card 
Sorting Test; WMS, Wechsler Memory Scale; WMS-R, Wechsler Memory Scale, Revised; WMS-III, Wechsler 
Memory Scale, Third Edition; WJ-III, Woodcock-Johnson Test of Cognitive Abilities, Third Edition; WRAML, 
Wide Range Assessment of Memory and Learning; WRAT, Wide Range Achievement Test. (=) no significant 
differences; (<) greater cognitive functioning. 
Summarizing the Literature 
 To date, three reviews and one meta-analysis have tried to clarify the evidence of 
neuropsychological studies in schizoaffective disorder. On review concluded that “schizophrenia 
and schizoaffective disorder share a similar pattern of cognitive impairments, which is distinct 
from patterns in major depression, bipolar disorder, and Alzheimer's dementia” (Buchanan et al., 
2005, p. 6). That review, however, was only based upon two studies (Evans et al., 1999; Miller et 
al., 1996). In a later review it was similarly concluded that individuals with schizoaffective 
disorder are similar to those with schizophrenia on most neuropsychological measures (Abrams 
Rojas, & Arciniegas, 2008). A recent systematic review determined schizoaffective disorder to 
be more cognitively similar to schizophrenia than bipolar disorder and concluded that 
schizoaffective disorder is either a subtype of schizophrenia or part of the continuum spectrum 
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model of psychosis, with schizoaffective disorder skewed more towards schizophrenia than 
bipolar disorder (Madre et al., 2016).  
 A meta-analysis of 31 studies that compared cognitive functioning across schizophrenia, 
schizoaffective disorder, and affective psychoses (Bora, Yucel, & Pantelis, 2009) reported how 
in 6 of 12 cognitive domains people with schizophrenia performed worse than the other two 
diagnostic groups. Specifically, the schizophrenia group performed significantly worse on verbal 
memory (immediate recall), intelligence, verbal working memory, TMT-Part B, and WCST 
performances. However, inter-group differences were slight and the distribution of effect sizes 
showed a substantial heterogeneity, leading the authors to conclude that neuropsychological data 
do not provide evidence for categorical differences between schizophrenia and schizoaffective 
disorder. 
 Of the 29 studies reviewed herein, only 10 concluded that there were significant cognitive 
differences between the diagnostic groups, with 9 of these reporting worse cognitive functioning 
in schizophrenia relative to schizoaffective disorder (see Table 3). Some of these studies 
supported the conceptualization of schizoaffective disorder as a heterogenous condition (e.g., 
Bornstein et al., 1990; Goldstein et al., 2005; Maj et al., 1986), separate diagnostic entity 
(Lindenmayer et al., 1989) or existing on a continuum (Heinrichs et al., 2008; Hill et al., 2013). 
In contrast, the majority of the literature reviewed (19 studies) found little or no support for 
categorical differences between the two groups based on neurocognitive performance (see Table 
4); however, it remains unclear as to which conceptualization of schizoaffective disorder these 
empirical studies support.  
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Comparing Social Cognition between Schizophrenia and Schizoaffective Disorder 
 Although neurocognition has been a long-standing focus in psychosis research in general 
and schizophrenia research in particular (see Green & Harvey, 2014), social cognition has 
emerged more recently as a high-priority research topic, especially due to its critical role in real 
world outcomes, such as social competence, community functioning, and quality of life (see 
Couture, Penn, & Roberts, 2006). Social cognition, generally defined as “the mental operations 
that underlie social interactions,” is comprised of four main overlapping domains: emotion 
processing, social perception, attribution bias, and theory of mind (Green & Horan, 2010, p. 
243). While social cognition represents the interface between emotional and cognitive 
processing, social cognition is distinct from neurocognition (for review, see Mehta et al., 2013).   
 Although individuals with schizophrenia perform significantly worse across multiple 
domains of social cognition compared to non-psychiatric individuals (Savla, Vella, Armstrong, 
Penn, & Twamley, 2013), only a few studies have compared social cognitive performance 
between schizophrenia and schizoaffective disorder, with findings being mixed (see Table 5). 
Thus, little is known about the degree to which impairments in social cognitive functioning 
represent endophenotypic markers of these illnesses (Eack et al., 2010) but it is believed that 
social cognition represents promising new endophenotypes (Gur et al., 2007). 
Studies Finding Superior Performance in Schizoaffective Disorder 
 Several studies have found that individuals with schizoaffective disorder have more intact 
social cognition relative to schizophrenia.  As previously mentioned, Fiszdon and colleagues 
(2007) reported no significant differences between the two diagnostic groups on a 
comprehensive battery of neurocognitive measures. Participants in this study were also 
administered two measures of social cognition: the Hinting Task (theory of mind) and the Bell-
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Lysaker Emotion Recognition Task (emotion perception). Individuals with schizoaffective 
disorder performed significantly better than those with schizophrenia on theory of mind but not 
affect perception (Fiszdon et al., 2007).  This suggests that persons with schizoaffective disorder 
may have more intact theory of mind performance, which refers to the ability to infer the mental 
states of others, but have impairments similar to schizophrenia patients with respect to emotion 
perception. 
 Chen and colleagues (2012) compared the performance of adults with schizophrenia (n = 
19), schizoaffective disorder (n = 15), and a non-psychiatric comparison group (n = 30) in two 
face-related cognitive tasks: emotion discrimination, which tests perception of facial affect, and 
identity discrimination, which tests perception of non-affective facial features. The schizophrenia 
group, but not the schizoaffective disorder group, exhibited deficient performance in both fear 
and happiness discrimination, as well as identity discrimination relative to the comparison group. 
The schizophrenia group showed significantly impaired performance in a theory of mind task 
compared to schizoaffective disorder and comparison groups; however, the schizoaffective 
disorder and comparison groups did not differ significantly. This pattern of results suggests 
distinct processing of face information in schizophrenia and schizoaffective disorder and lends 
empirical support to the notion that differential pathophysiological processes underlie social 
cognition in the two disorders.  
 Most recently, a pilot study in Israel (Tadmor et al., 2016) compared 40 clinically stable 
individuals with schizophrenia, 20 first episode-persons with schizophrenia, 9 individuals with 
schizoaffective disorder, and 200 comparison participants on the ‘Reading the Mind in the Eyes’ 
task (Eyes task) for which emotional expressions are identified based upon the eye regions of 
face images (total correct as well as negative emotional valence, positive emotional valance, and 
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neutral emotional valance were examined). The two schizophrenia groups did not differ 
significantly from each other but performed significantly worse than the comparison group in all 
Eyes test parameters. In contrast, the schizoaffective disorder group performed significantly 
better than the comparison group in decoding positive and neutral valance, with large effect size, 
but not negative valence (Tadmor et al., 2016). Moreover, the performance of the schizoaffective 
disorder group was significantly better than both schizophrenia groups in all Eyes test 
parameters.  
These results suggest that the presence of mood symptoms in schizoaffective disorder 
individuals is related to better processing of facial information, and might indicate that mood 
abnormality increases the sensitivity to social cues (Tadmor et al., 2016). This provides 
preliminary evidence that schizoaffective disorder might differ from schizophrenia in their 
ability to decode the mental state of other people, indicating that mentalizing might be an 
endophenotype in the diagnostic process of schizophrenia disorders. It is important to note that 
the small size of the study groups, especially the schizoaffective disorder group, is a major 
limitation of the study and that future studies with larger diagnostic groups are necessary to 
validate these findings. Moreover, a study that assessed the reliability and construct validity of 
the Eyes test rejected the three-factor structure “… on the basis of fit indexes and factor loading. 
This may be because the mental states in the test are sufficiently different to each other, so that 
they cannot easily be grouped into a small number of categories” (Vellante et al., 2013, p. 347).  
Studies Finding Equivalent Performance in Schizoaffective Disorder 
 Some studies have reported that social cognition does not differ between diagnostic 
groups.  One study concluded that inpatients with schizoaffective disorder (n = 29) performed 
significantly better on a task of social cognition (Picture Arrangement subtest of the Wechsler 
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Adult Intelligence Scale-Revised) relative to those with schizophrenia (n = 26). This difference, 
however, disappeared when a proxy measure of premorbid intelligence, a variable that 
significantly differed between the two groups, was covaried (Shean, Murphy, & Meyer, 2005). 
 In a study examining theory of mind, Greig and colleagues (Greig, Bryson, & Bell, 2004) 
compared Hinting Task performance among outpatients with DSM-III-R diagnosis of 
schizoaffective disorder and subtypes of schizophrenia. While the disorganized schizophrenia 
subtype (n = 12) performed significantly worse than the schizoaffective disorder group (n = 41), 
no significant performance differences were found between the schizoaffective disorder group 
and any of the other subtypes of schizophrenia (i.e., paranoid schizophrenia, n = 61; residual 
schizophrenia, n = 8; undifferentiated schizophrenia, n = 5) (Greig et al., 2004). In a study with 
youth, no significant differences were found among those with schizophrenia and schizoaffective 
disorder on theory of mind, as assessed by the Eyes task (Hooper et al., 2010). 
Summarizing the Literature  
 Of the few studies that have compared these diagnostic groups on social cognition, the 
majority have failed to include a comparison group and most have assessed only a single domain 
of social cognition. Social cognition, like other aspects of cognition, is a multifaceted concept, 
comprised of several interrelated sub-domains and processes. As such, multiple measures are 
important in order to adequately address the range of social cognitive abilities shown to be 
impaired among people with psychosis (see Savla et al., 2013).  More studies on this subject are 
needed as the current dearth of studies with mixed results means that no summary statement 
about social cognition can be made. Moreover, even fewer studies have compared these 
diagnostic groups on both social cognition and neurocognition and the findings from those that 
have (e.g., Fiszdon et al., 2007; Hooper et al., 2010) are limited to youth or veteran samples.  
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Overall the literature reviewed largely suggests that these two disorders are not distinct. It 
is interesting to note that the DSM-5 acknowledges “growing evidence that schizoaffective 
disorder is not a distinct nosological category” (APA, p. 90).  Nevertheless, it was retained in the 
DSM as an independent entity and remains a frequent diagnosis in clinical practice. Thus, this 
research study will further investigate the validity of schizoaffective disorder through objective, 
biologically valid means and sets to test the idea that schizoaffective disorder is not a distinct 
diagnostic entity. 
Table 5 
 Studies Comparing Social Cognition between Schizoaffective Disorder and Schizophrenia 
 
References Population Measures Main Findings  
 
Greig et al., 2004 SZ-P = 62, SZ-U= 
5, SZ-D = 12,  
SZ-R = 8, SA = 41 
 
Hinting Task SZ-D = SZ-U < SZ-P = SZ-
R = SA 
Shean et al., 2005 SZ = 26, SA = 29, 
BD = 18  
WAIS picture 
arrangement  
 
SZ = SA = BD 
Fiszdon et al., 2007 SZ = 199, SA = 73 BLERT, Hinting 
Task 
 
BLERT: SZ = SA 
Hinting task: SZ < SA 
Hooper et al., 2010 SZ = 79, SA = 40 Reading the Mind 
in the Eyes 
 
SZ = SA 
Chen et al., 2012 SZ = 19, SA= 15, 
CG = 30 
Reading the Mind 
in the Eyes 
 
SZ < SA = CG 
Tadmor et al., 2016 SZ-CS = 41, SZ-
FE = 20, SA = 9,  
CG = 200 
 
Reading the Mind 
in the Eyes 
SZ-CR = SZ-FE < CG < SA 
Note. SA, schizoaffective disorder; SZ, schizophrenia; SZ-P, schizophrenia paranoid; SZ-U, schizophrenia 
undifferentiated; SZ-R, schizophrenia residual; SZ-D, schizophrenia disorganized, SZ-CR, schizophrenia clinically 
stable; SZ-FE, schizophrenia first-episode; BD, bipolar disorder; CG, comparison group. BLERT, Bell Lysaker 
Emotion Recognition Task; WAIS, Wechsler Adult Intelligence Scale. (=) no significant differences; (<) greater 
cognitive functioning. 
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Objectives and Hypotheses 
The primary purpose of the present study was to determine whether schizophrenia and 
schizoaffective disorder are distinct or similar conditions by examining the extent to which they 
share underlying cognitive deficits.  This is the first study to assess whether schizophrenia and 
schizoaffective disorder are separable using a state-of-the-art, comprehensive cognitive battery 
designed specifically for the illness (Nuechterlein et al., 2008). While most studies to date have 
primarily attempted to distinguish these diagnostic categories by using neurocognitive measures, 
the current research breaks ground by comprehensively assessing and comparing both 
neurocognitive and social cognitive performances among a representative sample of community 
dwelling adults with schizophrenia and schizoaffective disorder, as well as a comparison group.  
Additionally, to provide a more detailed and comprehensive understanding of the ways in which 
these diagnostic categories differ and overlap demographic and clinical variables, as well as 
indicators of functionality, were examined.  
This study, however, is not only focused upon detecting differences between these 
diagnostic groups, but aims to determine whether neurocognitive and social cognitive 
performance can accurately classify individuals into schizophrenia and schizoaffective disorder 
diagnostic categories, as well as predict those without psychiatric illness. Understanding the 
ability of standardized measures to quantify the differences and similarities between diagnostic 
categories has important implications for enhancing the clinical practice of differential diagnosis, 
which currently relies upon subjective symptom reports. Thus, the findings from this study will 
speak to the utility of cognitive testing as a routine part of diagnosing psychotic disorders.   
  It was predicted that relative to the comparison group, both diagnostic groups will be 
significantly more impaired across all domains of neurocognitive and social cognitive 
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functioning. It was also expected that the two diagnostic groups would not differ significantly 
across neurocognitive domains and therefore neurocognitive performance would not be able to 
accurately predict diagnosis.  In contrast, it was hypothesized that individuals with 
schizoaffective disorder would perform significantly better on tasks of social cognition compared 
to those with schizophrenia but as little research has yet looked at this area it was unclear 
whether such a difference will be large enough to predict diagnosis.  This will be the first study 
to examine this. Last, it was predicted that the two diagnostic groups would not differ 
substantially on demographic or clinical features but the schizoaffective disorder group was 
anticipated to be more intact functionally than those with schizophrenia. 
Methods 
Participants 
 The clinical sample was comprised of 116 male and female individuals who met the 
following criteria: 1) a diagnosis of schizophrenia (n = 70) or schizoaffective disorder (n = 46) 
confirmed by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (First, Spitzer, 
Gibbon, & Williams, 2002); 2) outpatient status; 3) a history free of developmental or learning 
disability; 4) age 18 - 65; 5) a history free of neurological or endocrine disorder; and 6) no 
concurrent DSM-IV-TR (APA, 2000) diagnosis of substance use disorder. Participants in the 
comparison group (n = 146) were screened for medical and psychiatric illness and history of 
substance abuse. Demographic and clinical characteristics of the diagnostic groups and 
comparison group are reported in Table 6.  
 The clinical samples were recruited from three outpatient clinics in Hamilton, Ontario, 
Canada: the Cleghorn Early Intervention in Psychosis Program, the Hamilton Program for 
Schizophrenia, and the Community Schizophrenia Service. Participants in the comparison group 
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were recruited through local newspaper and online classified advertisements for paid research 
participation. All participants provided written informed consent on a form approved by the 
institutional review board. This study was part of a larger research project which was approved 
by the institutional review board at each research site and by York University. 
Measures 
 Demographic and clinical history. Patients’ medical charts were reviewed to determine 
presence, type, and dose of anti-psychotic medications. The presence and type of other 
psychotropic medications along with psychiatric, medical, and demographic data were recorded 
using the Social and Psychiatric History Schedule, which is a comprehensive record of 
information such as age, education, marital status, and vocational and psychiatric history. A 
screening questionnaire was used to gather demographic and medical history among comparison 
group participants.  
 Psychiatric diagnosis and symptom severity. Patients were administered the Structured 
Clinical Interview for DSM-IV-TR (SCID-I/II; First et al., 2002) to confirm psychiatric diagnosis. 
Trained clinical research staff used standard administration instructions and guidelines to gather 
diagnostic and symptom data. Psychiatric symptoms were assessed with the Positive and 
Negative Syndrome Scale (PANSS; Kay, Opler, Fiszbein, Ramirez, & White, 2000). This semi-
structured interview contains 30 items that are rated on a severity scale ranging from 1 (absence 
of psychopathology) to 7 (extremely severe). This measure contains subscales which provide an 
index of positive and negative symptoms, depressive symptoms, as well as general 
psychopathology. Higher scores indicate more severe symptoms.  
 Functionality. Two indicators of functionality were used for patients based on 
information obtained from the Social and Psychiatric History Schedule. These include 
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employment status (full-time, part-time, volunteer or unemployed) and living status (independent 
or assisted living).   
 Intelligence estimates. Participants’ premorbid intelligence was estimated using the 
Word Reading subtest from the Wide Range Achievement Test - Fourth Edition (WRAT-4; 
Wilkinson & Robertson, 2006). The standardized score was used and higher scores indicate 
higher estimated premorbid intelligence. An estimate of general intellectual ability was obtained 
from the Vocabulary and Matrix Reasoning subtests of the Wechsler Abbreviated Scale of 
Intelligence (WASI; Wechsler, 1999). Higher scores represent greater estimated intelligence.  
 Neurocognitive measures. Neurocognitive function was assessed using the MATRICS 
Consensus Cognitive Battery (MCCB; Nuechterlein et al., 2008), which was developed by the 
National Institute of Mental Health’s (NIMH) Measurement and Treatment to Improve 
Cognition in Schizophrenia (MATRICS) initiative. The MCCB is a reliable, consensus-based set 
of standards for measuring cognitive deficits that characterize schizophrenia and related 
disorders. Domain T scores (Processing Speed, Working Memory, Visual Learning and Memory, 
Verbal Learning and Memory, Reasoning and Problem Solving, and Attention/Vigilance) were 
calculated for each participant. These domains were assessed through the following: Processing 
Speed: Category Fluency: Animal Naming, Trail Making Test: Part A, and Brief Assessment of 
Cognition in Schizophrenia: Symbol Coding; Working Memory: Wechsler Memory Scale-III: 
Spatial Span and Letter-Number Span; Verbal Learning: Hopkins Verbal Learning Test Revised; 
Visual Learning: Brief Visuospatial Memory Test Revised; Reasoning and Problem Solving: 
Neuropsychological Assessment Battery: Mazes; and Attention: Continuous Performance Test – 
Identical Pairs (please see the Appendix for a more detailed description of each MCCB subtest).  
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 Social cognitive measures. The Reading the Mind in the Eyes test (Baron-Cohen, 
Wheelwright, Hill, Raste, & Plumb, 2001) is a widely used task of theory of mind which 
measures a person’s capacity to infer and discriminate the emotions of others from expressions in 
the eye region of the face. Participants viewed 36 photographs of the eye region from both 
female and male faces and had to select for each image which of four accompanying words best 
described the emotion that was being conveyed. Participants were awarded one point for each 
correct response with total scores ranging from 0-36. Higher scores indicate greater social 
sensitivity.  
 Emotion perception was assessed using the social cognition score from the MCCB. More 
specifically, the MCCB measures social cognition through the Managing Emotions subtest from 
the Mayer–Salovey–Caruso Emotional Intelligence Test, Version 2.0 (MSCEIT; Mayer, 
Salovey, & Caruso, 2002).  The ability to manage emotions is assessed through a series of 
scenarios asking the test-taker to identify the most adaptive ways to regulate or manage one’s 
own feelings (Emotion Management Task) and the feelings of others in social situations 
(Emotional Relationship Task). Higher scores reflect better ability to manage emotions. 
 The Internal, Personal, and Situational Attributions Questionnaire (IPSAQ; Kinderman & 
Bentall, 1996) measures the degree to which individuals generate internal, personal, or 
situational causal attributions for both positive and negative events. Externalizing Bias (EB) 
score was calculated by subtracting the number of internal attributions for negative events from 
the number of internal attributions for positive events. A positive score indicates a strong self-
serving bias or tendency to blame oneself less for negative events than for positive events (i.e., 
over attribute positive rather than negative events to oneself). Scores range from 16, indicating a 
strong self-serving bias, to -16, indicating a weak self-serving bias. Personalizing Bias (PB) 
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score was calculated by dividing the number of personal attributions by the sum of both personal 
and situational attributions for negative events. A score of greater than 0.5 represents a tendency 
to use personal, rather than situational, external attributions for negative events (i.e., blame 
others rather than situations for negative outcomes).  
Procedure 
 Participants in the present study were part of a larger research project preserved cognitive 
ability as well as impairments in individuals with a diagnosis of schizophrenia/schizoaffective 
disorder. This project, which occurred between 2010 and 2014 and was funded by Canadian 
Institute of Health Research (CIHR), aimed to provide the first detailed assessment of the 
psychopathology, cognition and structural brain biology of individuals with schizophrenia whose 
verbal abilities are cognitively exceptional compared to more typical patients with cognitive 
impairments and both exceptional and cognitively intact persons without psychiatric illness. This 
research was driven by the theory that the co-occurrence of schizophrenia and superior verbal 
ability represents a variant of schizophrenia whereby neural mechanisms generate severe 
psychopathology, but leave cognitive performance relatively unaffected. Thus, participants were 
recruited to cover a broad spectrum of cognitive abilities, such that those with a mental illness 
diagnosis not only had cognitive impairments but several were also cognitively “normal” 
(defined as an overall MCCB composite T score from 40 to 60). Similarly, those in the 
comparison group were recruited to include individuals functioning in the cognitively “normal” 
range as well as those in the “impaired” range (defined as an MCCB composite T score from 20 
to 39).  
 In the present study, after those with a psychiatric diagnosis provided signed informed 
consent, they underwent a structured diagnostic interview to confirm diagnosis. Following 
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confirmation of diagnosis, patients were administered the PANSS to assess symptom severity. 
Patients’ psychiatric, medical, and demographic data were recorded with the Social and 
Psychiatric History Schedule. Patients then completed the neurocognitive and social cognitive 
measures.  Once participants in the comparison group provided written informed consent, they 
were screened and excluded for medical and psychiatric illness. Those in the comparison group 
subsequently provided demographic information and completed neurocognitive and social 
cognitive measures.  
 Trained graduate-level psychology students and a research assistant administered all tests 
and interviews. The test battery and the clinical interviews took approximately 6 hours and were 
usually completed in two separate sessions, scheduled several days apart. All participants 
received monetary compensation for their time.  
Statistical Analyses  
 Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS), Version 23, as well as R Studio when certain tests were not available in SPSS. To 
overcome lack of normal distribution of demographic and clinical scores among groups, as well 
as violations of homogeneity of variance for several variables, robust methods were used (see 
Cribbie, Fiksenbaum, Wilcox, & Keselman, 2012) in R Studio. A series of heteroscedastic one-
way ANOVAs (Wilcox, 2012) for trimmed means (20%) were conducted to determine whether 
groups differed significantly on age, education, estimated premorbid intelligence, and estimated 
current intelligence. Significant findings were followed up with Yuen’s test for trimmed means 
(20%), which is a robust independent sample t-test (Yuen, 1974). The effect size of group 
differences was measured using Cohen’s d, which in this case was calculated by dividing the 
trimmed mean difference by pooled standard deviation (Cohen, 1988). Effect sizes of ≥0.20, 
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≥0.50 and ≥.80 were considered small, medium, and large, respectively. Statistical comparisons 
on discrete variables, such as sex, first language, and handedness, were conducted using 
Pearson’s chi-square test (or in cases where the assumption of this test was violated, i.e., 
expected frequencies of less than 5, the likelihood ratio statistic was used). The effect size of 
group differences was measured using Crammer’s V, which varies based on degrees of freedom.  
 The two diagnostic groups were compared on lifetime hospitalization, duration of illness, 
and severity of positive, negative, general, and depressive symptoms using Yuen’s test for 
trimmed means (Yuen, 1974). Discrete variables, such as medication status, employment status 
and living status, were compared using Pearson’s chi-square test or likelihood ratio statistic.  
 Analysis of the mean neuropsychological T-scores was conducted using a profile 
multivariate analysis of variance (MANOVA) to determine if there were significant differences 
among the three groups across cognitive domains. If a significant interaction of group by 
neurocognitive domain was noted, it was followed up with univariate ANOVAs to determine 
which neurocognitive domains differ between groups. Post-hoc statistical power was calculated 
for each ANOVA using GPower (Version 3.1) and was based upon the total sample size, 
adjusted alpha level, and effect size (which was determined from partial eta squared). Power 
equal to or greater than 0.80 was set as the standard for adequacy. If individual cognitive domain 
ANOVAs were significant, they were followed up with Games Howell post-hoc tests. The effect 
size of group differences was measured using Cohen’s d, which was calculated by dividing the 
mean difference by pooled standard deviation (Cohen, 1988). A discriminate function analysis 
was also performed to determine which linear combination of individual neurocognitive 
variables leads to maximum group distinction and to examine the degree to which 
neurocognitive performance could correctly predict group membership.   
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 Analysis of social cognitive measures was conducted using MANOVA to determine if 
there were significant differences among the three groups across social cognitive domains. If a 
significant interaction of group by social cognitive domain was noted, it was followed up with 
univariate ANOVAs and post-hoc statistical power was calculated for each ANOVA. If 
individual social cognitive domain ANOVAs were significant, they were followed up with 
Games-Howell post-hoc tests and the effect size of group differences was measured using 
Cohen’s d. A discriminate function analysis was performed to determine how the social 
cognitive domains discriminate the three groups, as well as to examine the degree to which social 
cognitive performance could effectively predict group membership. 
Results 
Demographic and Clinical Characteristics  
 As displayed in Table 6, group status was not significantly associated with sex, first 
language, or handedness, with all effect sizes being small (V = 0.12, V = 0.06, V = 0.11, 
respectively). Further, the three groups did not differ significantly in terms of age or years of 
education; however, they differed significantly on estimated premorbid intelligence and 
estimated current intelligence. In terms of estimated premorbid intelligence, there was a medium 
and significant difference between the diagnostic groups, t(52.70) = 2.66, p = .010, d = 0.61, 
such that those with schizophrenia (trimmed M = 89.29, SD = 10.82) scored significantly below 
those with schizoaffective disorder (trimmed M = 95.83, SD = 10.70). There was also a medium 
and significant difference between the schizophrenia and comparison groups, t(50.03) = 3.34, p = 
.002, d = 0.60, such that the schizophrenia group performed significantly worse than the 
comparison group (trimmed M = 95.54, SD = 10.16); however, the schizoaffective disorder and 
comparison groups did not differ significantly, t(33.50) = 0.145, p = .885, d = 0.03.  
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In terms of estimated current intelligence, while the schizophrenia group (trimmed M = 
93.30, SD = 17.80) scored below the schizoaffective disorder group (trimmed M = 99.57, SD = 
17.80), this difference was small and not statistically significant, t(53.95) = 1.44, p =.155, d = 
0.35. The performance of the schizophrenia group fell significantly below the comparison group 
(trimmed M = 102.20, SD = 15.23), t(86.24) = 3.03, p =.003, d = 0.54, whereas the 
schizoaffective disorder and comparison groups did not differ significantly, t(36.26) = .698, p 
=.490, d = 0.16.   
Table 6  
Demographic Comparison of Three Groups  
 
Demographic 
Variables 
 
Groups 
 
Group Comparisons 
 
 
 
SZ 
(n = 70) 
 
SA 
(n = 46) 
 
CG 
(N = 146) 
 
F, χ2 or Lχ2 
 
p 
Age in years, 
M(SD) 
41.39(11.36) 44.54(9.24) 40.34(11.18) F(2, 72.03) = 2.87 0.064 
Sex, n(%), 
male 
52(74.3) 29(63.0) 88(60.3) χ2(2) = 4.11 0.128 
Education in 
years, M(SD) 
12.46(2.15) 12.84(2.47) 11.95(2.28) F(2, 69.32) = 2.28 0.110 
First language, 
n(%), English 
62(88.6) 43(93.5) 134(91.8) χ2(2) = .96 0.618 
Handedness, 
n(%), right 
 65(92.9) 36(81.8) 125(86.2) χ2(2) = 3.29 0.193 
Premorbid IQ, 
M(SD) 
88.98(10.82) 94.61(10.70) 95.50(10.16) F(2, 49.6) = 5.78 0.006 
Current IQ 
M(SD) 
93.29(17.80) 98.83(17.80) 101.56(15.23) F(2, 58.75) = 4.56 0.014 
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Note. For purposes of clarity, untrimmed means and standard deviations are presented but all F values 
were based on trimmed means. Education was missing for one SZ participant; handedness was missing 
for one CG participant and two SA group participants; estimated premorbid IQ was missing for 14 SZ, 8 
SA and 2 CG participants; and current IQ was missing for 1 SZ group participant. SZ = schizophrenia; 
SA = schizoaffective disorder; CG = comparison group.  
 
 Table 7 summarizes clinical variables among the two diagnostic groups. The two 
diagnostic groups did not differ significantly in terms of the number of lifetime hospitalizations 
or the number of years since the onset of first characteristic signs and symptoms. The two 
diagnostic groups also did not differ significantly in terms of general psychiatric, positive or 
negative symptom severity. There was a medium and significant difference between diagnostic 
groups on depressive symptom severity, such that the schizoaffective group had significantly 
more severe depressive symptoms than the schizophrenia group. 
  In terms of functionality, employment status and living status were assessed. There was a 
medium but non-significant association between diagnostic category and employment status. 
With respect to living status, there was a medium and significant association between diagnostic 
category and living status, such that those with schizophrenia were significantly less likely to 
live independently than those with schizoaffective disorder.   
 The majority of patients (N = 83) were medicated with only one patient being un-
medicated (data for 33 patients was missing). The proportion of patients medicated or not 
medicated did not differ significantly between the diagnostic groups. There was no significant 
difference in the class of anti-psychotic medication (i.e., typical, atypical or combination) 
between diagnostic groups. The diagnostic groups also did not differ significantly in terms of the 
proportion taking or not taking anti-depressants, mood stabilizers, benzodiazepines, and anti-
Parkinson agents. All effect sizes were small.  Overall, the demographic and clinical features of 
the current sample of participants with schizophrenia and schizoaffective disorder is 
 
 
39 
 
representative of community dwelling research participants with psychotic disorder (see 
Cheniaux et al., 2008; Heinrichs & Zakzanis, 1998). 
Table 7 
Clinical Comparison of Schizophrenia and Schizoaffective Disorder Groups 
 
Clinical Variables 
 
Diagnostic Groups 
 
Group Comparisons 
 
 
 
 
 
SZ 
(n = 70) 
 
SA 
(n = 46) 
 
 
t, χ2 or Lχ2 
 
 
p 
 
 
Effect size 
Symptom 
severity, M(SD) 
 
     Positive  
     Negative  
     Depression  
     General  
 
 
 
43.81(9.18) 
40.80(8.14) 
47.67(11.70) 
41.30(7.14) 
 
 
 
42.52(8.77) 
37.87(5.96) 
54.87(12.71) 
42.72(8.10) 
 
 
 
t(45.93) = 0.589 
t(66.990) = 1.660 
t(52.17) = 2.699 
t(44.14) = 1.075 
 
 
 
0.559 
0.102 
0.009 
0.288 
 
 
 
d = 0.13 
 
d = 0.40 
 
d = 0.60 
 
d = 0.26 
Years of 
Illness, M(SD) 
 
17.45(12.15) 
 
17.34(8.75) 
 
t(47.51) = 0.211 
 
 
0.834 
 
d = 0.06 
Hospitalizations  
(lifetime), M(SD) 
 
4.61(6.38) 
 
5.46(7.29) 
 
t(35.35) = 0.511 
 
0.613 
 
d = 0.06 
 
Employment 
status, n(%) 
 
     Full-time 
 
     Part-time 
 
     Volunteer 
 
     Unemployed 
 
 
4(7.7) 
 
2(3.8) 
 
20(38.5) 
 
25(50.0) 
 
3(8.3) 
 
7(19.4) 
 
11(30.6) 
 
 
15(41.7) 
 
Lχ2(3) = 5.80 0.122 V = .26 
Living status, 
n(%) 
 
     Independent  
 
 
 
15(44.1) 
 
 
 
19(73.1) 
 
χ2(1) = 5.032 
 
 
0.025 
 
V = .290 
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     Assisted 
 
 
19(55.9) 
 
7(26.9) 
Medicated, n(%)  47(57.3) 35(42.7) Lχ2(1) = 1.104 0.293 V=.094 
Anti-Psychotic 
Type, n(%) 
 
…..Typical only 
 
…..Atypical only 
 
…..Both types 
 
 
 
 
8(17.8) 
 
32(71.1) 
 
5(11.1) 
 
 
 
4(12.5) 
 
26(81.3) 
 
2(6.3) 
 
Lχ2(2) = 1.104 
 
0.576 
 
V = .118 
Anti-Depressant,  
 
21(43.8) 18(51.4) χ2(1) = .479 0.489 V = .076 
Mood Stabilizers 
 
5(10.4) 6(17.1) Lχ2(1) = .786 0.375 V = .098 
Benzodiazepines 
 
17(35.4) 15(42.9) χ2(1) = .473 0.492 V = .075 
Anti-Parkinsonian 
 
5(10.6) 8(22.9) χ2(1) = 2.245 0.134 V = .165 
Note. For purposes of clarity, untrimmed means and standard deviations are presented but all t values are 
based on trimmed means. Sample sizes varied and are as follows: years of illness (SZ = 47, SA = 33); 
lifetime number of hospitalizations (SZ = 51, SA = 35); employment status (SZ = 52, SA = 36); living 
status (SZ = 34, SA = 26); Anti-psychotic (SZ = 45, SA = 32); Anti-depressants (SZ = 48, SA = 35); 
Mood stabilizers (SZ = 48, SA = 35); Benzodiazepines (SZ = 48, SA = 35); Anti-Parkinsonian (SZ = 47, 
SA= 35). M = mean; SD = standard deviation. SZ = schizophrenia; SA = schizoaffective disorder.  
Comparing Neurocognitive Domains 
 The sample of participants with neurocognitive data was smaller than the overall sample 
with a total of 242 participants (58 schizophrenia, 39 schizoaffective disorder, and 145 
comparison) having complete neuropsychological data. The respective groups with complete 
data were compared on demographic and clinical variables. The findings were consistent with 
what was reported above in Tables 6 and 7, except that years of education differed significantly 
between groups, F(2, 56.65) = 3.19, p = .048. The schizophrenia (trimmed M = 12.69, SD = 
1.99) and schizoaffective disorder (trimmed M = 12.82, SD = 2.50) groups did not differ 
significantly, t(46.09) = .290, p = .773, d = 0.06. The comparison group (trimmed M = 11.99, SD 
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= 2.27) had significantly fewer years of education than schizophrenia group, t(71.69) = 2.10, p = 
.040, d = 0.34, and schizoaffective disorder group, t(37.85) = 1.95, p =.058, d = 0.35.  
Assumptions for MANOVA were assessed. All observations were independently 
distributed, all neurocognitive outcome variables were continuous, and the sample sizes in each 
group were adequate. Based on Mahalanobis distance (df = 6, cut off = 22.46) one multivariate 
outlier was identified amongst the residuals (22.67). Outliers were examined and overall no 
values had extreme leverage (all hat values were less than 1, with a maximum value of .094) or 
influence (all Cook’s distance values were less than 1, with a maximum value of .060). As SPSS 
does not have a test of multivariate normality, this was conducted in R Studio using Mardia’s 
multivariate test of normality. Based on the residuals of all of the neurocognitive variables, the 
skewness (Mardia’s = 2.96, χ2 =119.33, p < .001) and kurtosis (Mardia’s = 48.66, χ2 = -.53, p = 
.598) estimates indicate that the distribution of the residuals is not multivariate normal. Visual 
inspection of a chi-square Q-Q plot indicates that this deviation from multivariate normality is 
mild. Box’s test of equality of covariance matrices was violated, M = 65.74, F(42, 44137.30) = 
1.49, p = .022; however, this is likely because this test is susceptible to deviations from 
multivariate normality. There is no multicollinearity (correlations between outcome variables 
were less than 0.9) and neurocognitive outcome variables were moderately correlated with each 
other, with values ranging from .430 to .686.    
 The omnibus MANOVA showed a significant difference between groups in terms of 
neurocognitive performance, Λ = 0.70, F(12, 468) = 7.53, p < .001. To check for the impact of 
potential outliers, a simple robust method that iteratively down weights the observations with 
large multivariate residuals was performed in R Studio with essentially the same results, Λ = 
0.67, F(12, 468) = 8.515, p < .001. The omnibus MANOVA was followed up with separate 
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univariate ANOVAs and multiple comparisons were adjusted using a Bonferonni correction, 
α(.05/6) = .008. Levene’s assumption of equality of homogeneity variance was upheld for all 
ANOVAs. The ANOVAs showed that the groups differed significantly on all neurocognitive 
domains (all p-values < .001) and that power was adequate. See Table 8 and Figure 1. 
Table 8  
Neurocognitive Domain Mean (SD) T-Scores and Between Groups Mean Comparison 
Neuro-
cognitive 
Domains 
 
Groups 
 
One-way ANOVAs 
 
 
 
SZ 
(n = 58) 
 
SA 
(n =39) 
 
CG 
(n = 145) 
 
F(2, 
239) 
 
p 
 
Partia
l η2 
 
Power 
Processing 
Speed 
33.10(11.84) 33.15(9.23) 45.12(10.45) 37.069 < .001 .237 1.00 
Attention 33.45(13.25) 34.56(13.18) 43.67(12.28) 17.399 < .001 .127 .998 
Working 
Memory 37.33(11.92) 38.08(12.81) 45.66(11.18) 13.908 < .001 .104 .988 
Verbal 
Learning 35.66(9.07) 36.54(8.73) 44.96(9.44) 27.346 < .001 .186 .999 
Visual 
Learning 
 
32.31(11.98) 32.39(9.96) 40.31(10.12) 16.607 < .001 .122 .997 
Reasoning/ 
Problem 
Solving 
 
41.36(8.80) 39.92(8.61) 49.20(9.37) 25.062 < .001 .173 .999 
Note. SD = standard deviation; SZ = schizophrenia; SA = schizoaffective disorder; CG = comparison group. 
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Figure 1. Boxplots comparing the performance between groups on neurocognitive domains.  
White dots represent group means (as reported in Table 3). Speed = processing speed; Memory = 
working memory; Verbal = verbal learning; Visual = visual learning; ProbSolv = problem 
solving.  
Games-Howell post-hoc comparisons demonstrated that on all neurocognitive domains, 
the schizophrenia group performed significantly worse than the comparison group (all p < .001). 
This produced the following rank order: processing speed (d = 1.08), verbal learning (d = 1.00), 
reasoning/problem solving (d = 0.86), attention (d = 0.80), working memory (d = 0.72) and 
visual learning (d = 0.72). The schizoaffective disorder group also performed significantly worse 
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than the comparison group on all neurocognitive domains (all p < .001, except attention, p = 
.001, and working memory, p =.004). This produced the following rank order: processing speed 
(d = 1.21), reasoning/problem solving (d = 1.03), verbal learning (d = 0.93), visual learning (d = 
0.79), attention (d = 0.72), and working memory (d = 0.63). While the schizophrenia group 
performed slightly worse than the schizoaffective disorder group on all neurocognitive domains, 
except for reasoning/problem solving (see Table 8), the differences between the two diagnostic 
groups was not statistically significant (all p values > .70) and effect sizes were small (Cohen’s d 
ranged from 0.005 to 0.17). 
 The MANOVA was followed up with discriminant analysis, which revealed two 
discriminant functions. The first function explained 98.5% of the variance in the group means, 
while the second only explained 1.5% of variance in group means. In combination these 
discriminant functions significantly differentiated the groups, Λ = .70, χ2(12) = 83.47, p < .001, 
but removing the first function indicated that the second function did not significantly 
differentiate the groups, Λ = .99, χ2(5) = 1.48, p = .915.  Thus, the significant difference from 
the MANOVA between the comparison group and two diagnostic groups can best be explained 
in terms of one underlying dimension. Moreover, what most strongly differentiated the 
comparison group from the two diagnostic groups was performance on tasks of processing speed 
(r = .625), verbal learning (r = .446) and reasoning/problem solving (r =. 396). See Figure 2.  
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Figure 2. Canonical discriminant function plot of neurocognitive domains by group.  This figure 
indicates that problem solving, processing speed and verbal leaning are the neurocognitive 
domains that most discriminate the three groups. The group centroids are denoted with a cross, 
with the schizophrenia, schizoaffective disorder and comparison group centroids represented by 
a black, dark grey, and light grey cross, respectively. Black circles represent participants in the 
schizophrenia group, dark grey triangles represent individuals in the schizoaffective disorder 
group, and light grey squares represent individuals in the comparison group. ProbSolv = problem 
solving; Speed = processing speed; Visual = visual learning; Verbal = verbal learning; Memory 
= working memory.  
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The discriminant function analysis was also performed to examine the degree to which 
cognitive performance could correctly classify individuals as having schizophrenia, 
schizoaffective disorder or no psychiatric condition (comparison).  See Table 9. Of the 58 
individuals in the schizophrenia group, the cognitive measures only correctly identified 51.7% (n 
= 30) of people with schizophrenia as such. Of the 39 individuals with schizoaffective disorder, 
the cognitive measures were only able to correctly identify 7.7% (n = 3). The majority of 
individuals with schizoaffective disorder were incorrectly classified as belonging to the 
comparison group, 48.7% (n = 19), or schizophrenia group, 43.6% (n = 17).  
Of the 145 participants in the comparison group, the cognitive measures were able to 
correctively identify the vast majority of participants, 93.8% (n = 136). No participants in the 
comparison group were misclassified as belonging to the schizoaffective disorder group and only 
6.2% (n = 9) were incorrectly classified as belonging to the schizophrenia group. Overall, 69.8% 
of the original grouped cases were correctly classified. 
Table 9 
Predicted Group Membership Based on Neurocognitive Performance 
Actual Group membership Predicted Group Membership  
 Schizophrenia Schizoaffective  
Disorder 
Comparison Total 
Schizophrenia, n(%) 30(51.7) 1(1.7) 27(46.6) 58 
Schizoaffective, n(%) 17(43.6) 3(7.7) 19(48.7) 39 
Comparison, n(%) 9(6.2) 0(0) 136(93.8) 145 
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Comparing Social Cognitive Domains 
 The sample of participants with social cognitive data was smaller than the overall sample 
with a total of 139 participants (43 schizophrenia, 30 schizoaffective disorder, and 66 
comparison) having complete social cognition data. The respective groups with completed data 
were compared on demographic and clinical variables. The findings were consistent with what 
was reported above in Tables 5 and 6, except that the three groups no longer differ significantly 
with respect to estimated current intelligence, F(2, 41.55) = 2.835, p =.070. 
 Assumptions for MANOVA were assessed. All observations were independently 
distributed, all social cognitive outcome variables were continuous, and the sample sizes in each 
group were adequate. Based on Mahalanobis distance (df = 4, cut off = 18.47) there were no 
multivariate outliers identified and all Cook’s distance and hat values fell well below one. Based 
on the residuals of all of the social cognitive variables, the skewness (Mardia’s = 1.23, χ2 =28.54, 
p = .097) and kurtosis (Mardia’s = 22.86, χ2 = -.97, p = .330) estimates, along with visual 
inspection of a chi-square Q-Q plot, indicate that the distribution of the residuals is multivariate 
normal. Box’s test of equality of covariance matrices was not violated, Box’s M = 16.83, F(20, 
33921.57) = .801, p = .715. There was no multicollinearity (correlations between outcome 
variables were less than 0.9) and social cognitive outcome variables were weakly correlated with 
each other, with values ranging from -.066. to .437.    
 The omnibus MANOVA showed a significant difference between groups in terms of 
performance on tasks assessing social cognition, Λ = 0.80, F (8, 266) = 3.930, p < .001. This was 
followed up with separate univariate ANOVAs that were adjusted for multiple comparisons 
using a Bonferroni correction at α(.05/4) = .013. Levene’s assumption of equality of 
homogeneity variance was upheld for all ANOVAs. The ANOVAs indicated that the groups 
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differed significantly on managing emotions and theory of mind but not on externalizing or 
personalizing attribution bias; however, this could be due to inadequate statistical power. See  
Table 10 and Figure 3.   
Table 10 
Social Cognitive Domain Mean (SD) T-Scores and Between Group Mean Comparison 
 
Social Cognitive  
Abilities 
Groups One-way ANOVAS 
 
 
 
 
SZ 
(n = 43) 
 
SA 
(n =30) 
 
CG 
(n = 66) 
 
F(2, 
136) 
 
p 
 
partial 
η2 
 
Power 
Managing 
Emotions 
35.83(11.32) 
 
44.53(12.80) 45.05(13.29) 7.666 .001 .101 .86 
Theory of Mind 20.81(5.58) 22.87(4.50) 24.98(5.57) 7.967 .001 .105 .88 
Externalizing 
Attribution Bias 
1.16(3.61) 2.10(4.29) 2.77(3.57) 2.409 .094 .034 .28 
Personalizing 
Attribution Bias 
.68(.29) .71(.24) .58(.27) 2.855 .061 .040 .35 
Note. SD = standard deviation; SZ = schizophrenia; SA = schizoaffective disorder; CG = comparison group.   
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Figure 3. Boxplots comparing the performance between groups on social cognitive domains.  
The three groups were compared in terms of their performance on social cognitive tasks 
assessing managing emotions, theory of mind, externalizing bias and internalizing bias. White 
dots represent group means (as reported in Table 6). 
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The two significant ANOVAs were followed up with Game-Howell post-hoc 
comparisons. In terms of managing emotions, the schizophrenia group performed significantly 
worse than both the comparison group (p = .001), with a medium effect (d = 0.74), and the 
schizoaffective disorder group (p = .011), with a medium effect (d = 0.75). While the 
schizoaffective disorder group performed slightly worse than the comparison group, this 
difference was non-significant (p = .982, d = 0.02).  
With respect to theory of mind, the schizophrenia group performed significantly worse 
than the comparison group (p = .001), with a medium effect (d = 0.77). Although the 
schizophrenia group performed worse, on average, than the schizoaffective disorder group, this 
difference was not statistically significant (p = .199, d = -0.48). The schizoaffective disorder and 
comparison groups did not differ significantly (p = .125, d = -0.38). 
 The omnibus MANOVA was followed up with discriminant analysis, which revealed two 
discriminant functions. The first function explained 84.9% of the variance in the group means, 
while the second explained 15.1% of variance in group means. In combination these discriminant 
functions significantly differentiated the groups, Λ = .800, χ2(8) = 30.054, p < .001, but 
removing the first function indicated that the second function did not significantly differentiate 
the groups, Λ = .965, χ2(3) = 4.839, p = .184.  Thus, the significant MANOVA can best be 
explained in terms of one underlying dimension. Moreover, what most strongly differentiated the 
groups was theory of mind (r =.583) and managing emotions (r =. 413). See Figure 4.  
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Figure 4. Canonical discriminant function plot of social cognitive domains by group. 
Theory of mind and managing emotions are the social cognitive variables that most discriminate 
the schizophrenia group from the other two groups. The group centroids are denoted with a 
cross, with the schizophrenia, schizoaffective disorder, and comparison group centroids 
represented by a black, dark grey, and light grey cross, respectively. Black circles represent 
participants in the schizophrenia group, dark grey triangles represent individuals in the 
schizoaffective disorder group, and light gray squares represent individuals in the comparison 
group. ExternalBias = externalizing bias; ToM = theory of mind; ManageEmotions = managing 
emotions; PersonalBias = personalizing bias.  
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The discriminant function analysis was also performed to examine the degree to which 
social cognitive performance could correctly classify individuals as belonging to the 
schizophrenia, schizoaffective disorder or comparison group. See Table 11. Of the 43 individuals 
in the schizophrenia group, the social cognitive measures only correctly identified 55.8% (n = 
24) as such, whereas 44.2% (n =11) were incorrectly classified as belonging to the comparison 
group. Nobody with schizophrenia was misclassified as belonging to the schizoaffective disorder 
group. Of the 30 individuals in the schizoaffective disorder group, only 3.3% (n = 1) were 
correctly classified as such based on the social cognitive measures. The majority of individuals 
with schizoaffective disorder, 70% (n = 20), were incorrectly classified as belonging to the 
comparison group and the remaining 26.7% (n = 8) were incorrectly classified as belonging to 
the schizophrenia group.  
Of the 66 participants in the comparison group, the vast majority, 86.4% (n = 57), were 
correctly classified as such, with only 9.1% (n = 6) and 4.5% (n = 3) incorrectly classified as 
belonging to the schizophrenia and schizoaffective disorder groups, respectively. Overall, 59.0% 
of the original grouped cases were correctly classified.  
Table 11 
Predicted Group Membership Based on Social Cognitive Performance 
Actual group membership Predicted Group Membership  
 Schizophrenia Schizoaffective 
disorder 
Comparison Total 
Schizophrenia, n(%) 24(55.8) 0(0) 19(44.2) 43 
Schizoaffective disorder, n(%) 8(26.7) 1(3.3) 21(70.0) 30 
Comparison, n(%) 6(9.1) 3(4.5) 57(86.4) 66 
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Discussion 
 Schizoaffective disorder represents an ongoing challenge for psychiatric nosology, given 
the uncertainty of its boundaries in relation to schizophrenia.  Using the MCCB, the current 
study found that the cognitive profile of individuals with a diagnosis of schizoaffective disorder 
and schizophrenia did not differ significantly. This is consistent with several previous findings 
(Amann et al., 2012; Beatty et al., 1993; Evans et al., 1999; Fiszdon et al., 2007; Gilvarry et al., 
2001; Glahn et al., 2006; Gooding & Tallent, 2002; Hooper et al., 2010; Manschreck et al., 1997; 
Miller et al. 1996; Moses, 1984; Owoso et al., 2013; Pinna et al., 2014; Reichenberg et al., 2009; 
Roofeh et al., 2006; Savage et al., 2003; Silverstein et al., 1988; Szoke et al., 2008; Townsend et 
al., 2001) including a recent systematic review of the literature (Madre et al., 2016). While the 
performance of the schizophrenia group on each cognitive domain was, on average, slightly 
below that of the schizoaffective disorder group (except on tasks of reasoning and problem 
solving), these differences were of small effect and non-significant. As such, these results are 
inconsistent with studies reporting cognitive heterogeneity across these diagnostic groups (e.g., 
Bornstein et al., 1990; Goldstein et al., 2005; Maj et al., 1986) and do not support the 
conceptualization of schizoaffective disorder as cognitively distinct from schizophrenia 
(Lindemayer et al., 1989) or as existing on a continuum of cognitive impairment (Heinrichs et 
al., 2008; Hill et al., 2013). Rather, these data suggest that global cognitive impairment is a 
shared feature of both disorders. 
 In light of the small and non-significant neurocognitive differences between the 
diagnostic groups, it is not surprising that cognitive performance was poor at classifying patients 
as having a diagnosis of schizophrenia or schizoaffective disorder.  In the current study, only 
51.7% of patients with schizophrenia and 7.7% of those with schizoaffective disorder were 
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correctly classified as such, suggesting substantial overlap between these diagnostic groups on 
cognitive functioning. Even among previous studies that found significant cognitive differences 
between patients with schizophrenia and schizoaffective disorder (e.g., Heinrichs et al., 2008; 
Torniainen et al., 2012), those differences were insufficient in magnitude to differentiate the 
diagnostic groups because the distributions overlapped, lending further to support to the finding 
that these disorders are more neurocognitively similar than they are distinct. Thus, the present 
findings suggest that including cognitive variables in the next version of the DSM will not help to 
increase the distinction between schizophrenia and schizoaffective disorder. Nevertheless, some 
scholars in the area have argued that including cognitive impairment in the diagnostic criteria 
and/or as a specifier may help clinicians target and potentially improve cognition in those living 
with psychotic disorders (see Bora, Yucel, & Pantelis, 2010; Keefe & Fenton, 2007).  
As predicted, both diagnostic groups performed significantly worse then the comparison 
group on all neurocognitive domains, with such differences being of a large magnitude. This is 
consistent with numerous other studies (e.g., Amann et al., 2012; Gooding & Tallent, 2002; 
Manschreck et al., 1997; Owoso et al., 2013; Roofeh et al., 2006). Moreover, cognitive 
performance was able to accurately predict not having a psychiatric illness as the vast majority of 
participants in the comparison group (93.8%) were correctly classified as such, lending further 
support to the notion that the neurocognitive performance of the comparison group is generally 
distinct from both diagnostic groups. Additionally, what most strongly differentiated the 
diagnostic groups from the comparison group was significantly poorer performance among the 
diagnostic groups on tasks of processing speed, verbal learning, and reasoning/problem solving. 
Another study also using the MATRICS similarly found that performance on speed of processing 
 
 
55 
 
best distinguished individuals with schizophrenia from community residents (see Kern et al., 
2011).  
With respect to social cognition, it was predicted that the schizophrenia group would be 
more impaired on all tasks compared to the schizoaffective disorder group; however, the two 
diagnostic groups only differed significantly from each other on a task of managing emotions. 
Specifically, participants in the schizophrenia group were significantly impaired on managing 
emotions relative to participants in both the schizoaffective disorder and comparison groups 
(medium effect sizes), while the schizoaffective disorder group was intact relative to the 
comparison group (small but non-significant difference). This suggests that the presence of mood 
symptoms in the schizoaffective disorder group may be related to having more adaptive methods 
for regulating and managing their own emotions and the feelings of others in social situations 
than those with schizophrenia. This provides limited support for a distinction between the two 
diagnostic categories. 
  In terms of theory of mind, there was a medium but non-significant difference in 
performance between the schizophrenia and schizoaffective disorder groups. This lack of 
statistical difference was not due to inadequate power and is consistent with some previous 
findings (see Greig et al., 2004; Hooper et al., 2010).  However, findings remained mixed as 
other studies have found schizophrenia patients to perform significantly worse on theory of mind 
tasks than schizoaffective disorder patients (see Chen et al., 2012; Fiszdon et al., 2007; Tadmor 
et al., 2016).  The present research also found that those in the schizophrenia group were 
significantly more impaired in theory of mind than the comparison group (medium effect), which 
is consistent with former studies (Chen et al., 2012; Tadmor et al., 2016). Findings are more 
mixed when it comes to comparing individuals in the schizoaffective disorder group to those in 
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the comparison group. While Tadmor and colleagues (2016) found that those with 
schizoaffective disorder scored significantly higher than the comparison group on theory of 
mind, the current study, as well as a previous study by Chen and colleagues (2012), found a non-
significant difference between the schizoaffective disorder and comparison groups. 
 Last, the three groups did not differ significantly from each other on attribution bias. This 
could be due to a lack of statistical power; however, the lack of significant difference between 
the schizophrenia and comparison group is consistent with previous findings. For instance, a 
meta-analysis found no significant differences in attribution style (as assessed by the IPSAQ) 
between a schizophrenia group and a comparison group (see Savla et al., 2013). The current 
study is the first to compare persons with schizophrenia and schizoaffective disorder on 
attribution bias and thus no comparison to previous findings can be made at this time. As such, 
further studies, with larger sample sizes, are needed and other measures of attribution style 
should also be considered (see Savla et al., 2013).  
 Despite the schizophrenia group exhibiting significantly impaired theory of mind relative 
to the comparison group, and despite significant deficits in the schizophrenia group on managing 
emotions compared to the comparison and schizoaffective disorder groups, these differences did 
not translate into high rates of classification accuracy. Among those with schizophrenia only 
55.8% were correctly classified and only 3.3% of those with schizoaffective disorder were 
accurately identified.  Thus, performance on social cognitive tasks was poor at accurately 
predicted and distinguishing diagnostic category. In contrast, the majority of individuals in the 
comparison group (86.4%) were correctly classified. 
 In addition to the lack of neurocognitive and social cognition differentiation between the 
diagnostic groups, the present study also found few significant differences between these groups 
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on most of the demographic and clinical variables, which is consistent with previous research 
(see Cheniaux et al., 2008). The two major clinical differences were that those with 
schizoaffective disorder had more severe depressive symptoms and less functional impairment as 
assessed by independent living status.  While these differences could be factors that truly 
distinguish these two groups, these could also reflect differences in underlying diagnostic 
criteria. The present data found a strong resemblance of participants diagnosed with 
schizoaffective disorder to those with schizophrenia in terms of demographic characteristics, 
symptomatology, and neurocognitive and social cognitive profiles and do not support the validity 
of schizoaffective disorder as separate from schizophrenia.  
Limitations, Strengths, and Future Directions 
 Several different conceptualizations of schizoaffective disorder have been proposed.  
Based on the current findings, it is unclear which conceptualization of schizoaffective disorder 
the data support as these findings are consistent with various alternative conceptualizations 
(Gooding & Tallent, 2002).  Further, it may be the case that these different conceptual views are 
complementary (Szoke et al., 2003).  In order to fully understand the co-occurrence of psychosis 
and cognitive impairment and whether it holds true across the schizophrenia-bipolar disorder 
continuum, a bipolar disorder group needs to be included. A recent systematic review of the 
literature addressed this issue and concluded that neurocognitively, individuals with 
schizoaffective disorder are more similar to those with schizophrenia than those with a diagnosis 
of bipolar disorder (Madre et al., 2016); however, these three diagnostic groups have not yet 
been compared in terms of social cognition.  
Importantly, continuing to compare diagnostic groups based on phenomenological 
manifestations, as done in the present study, only serves to recapitulate current DSM 
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nomenclature, which at present lacks biological validity. Thus, future research is encouraged to 
look across diagnostic categories to determine whether cognitive impairment is a transdiagnostic 
feature and whether or not there are particular patterns of cognitive impairment that can be used 
as an organizing principle instead of symptoms. Since 2009 the NIMH Research Domain Criteria 
(RDoC) initiative has been attempting to develop new ways of classifying mental illnesses based 
on dimensions of observable behaviour and neurobiological measures (including cognition), as 
opposed to descriptive phenomenology (see Cuthbert & Insel, 2010).  Consistent with the RDoC 
initiative is the Bipolar Schizophrenia Network on Intermediate Phenotypes (BSNIP) in which 
individuals were pooled across multiple diagnostic groups in the psychosis spectrum without 
regard to traditional diagnostic categories. The investigators studied a range of variables across 
levels of analysis and used statistical techniques to identify clusters of individuals based on 
patterns in the data that were independent of traditional diagnostic categories (see Clementz et 
al., 2016). 
There are other limitations that should be noted with regard to the present study. Due to 
unequal sample sizes, the neurocognitive and social cognitive MANOVAs did not take 
advantage of all data points. However, this analysis was preferred over conducting multiple 
ANOVAs since MANOVA reduces the likelihood of Type I errors. Additionally, most studies, 
including the current study, are cross-sectional in nature, which can be a limitation as the 
diagnosis of schizoaffective disorder has been shown to be unstable over time (see Malaspina et 
al., 2013). However, a longitudinal study by Stip and colleagues (2005) found that cognitive 
differences between schizophrenia and schizoaffective disorder remained stable over a two-year 
period.  
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The current research project also used a basic estimate of functioning (i.e., employment 
status and living status); however, functional outcome is a multifaceted construct and more 
comprehensive measures that assess different domains of functioning have been developed and 
validated for use among persons with psychosis (for a brief discussion see Lepage et al., 2014). 
Finally, there is no consensus about which measures of social cognition best index a given social 
cognitive domain. The majority of social cognition measures have poor psychometric properties 
(see Pinkham et al., 2013). As such, the Social Cognition Psychometric Evaluation (SCOPE) 
study is attempting to identify and improve the best existing measures of social cognition 
(Pinkham et al., 2013).  Future research may want to include different measures of social 
cognition, as well as have a larger sample size to increase statistical power.  
 The present work also had several strengths. This study replicated previous findings that 
schizophrenia and schizoaffective disorder are not neurocognitively distinct.  While other studies 
may not have found neurocognitive differences between groups due to small sample size (e.g., 
Savage et al., 2003; Townsend et al., 2001), this study had adequate sample size and statistical 
power to detect group differences. Moreover, by recruiting patients at the upper end of cognitive 
functioning and comparisons participants at the lower end of cognitive abilities, it ensured that 
our sample covered the full spectrum of cognitive abilities found among these diagnostic groups, 
as well as among the comparison group. This research has also enhanced the field by being the 
first study to compare these two diagnostic groups using a state-of-the-art, comprehensive 
cognitive battery designed specifically for the illness (Kern et al., 2008; Nuechterlein et al., 
2008). Additionally, this study is one of the few to compare schizophrenia and schizoaffective 
disorder patients on both neurocognitive and social cognitive measures. To date only two other 
studies have done so but the generalizability of those studies findings are limited to veterans 
 
 
60 
 
(Fiszdon et al., 2007) and youth (Hooper et al., 2010). Moreover, this is the first study to 
compare these diagnostic groups on multiple domains of social cognition. Although social 
cognitive measures in general are not standardized and have poor psychometric properties, this 
study used the MSCEIT and Eyes test, both of which are well-validated (e.g., Eack et al., 2010; 
Vellante et al., 2013).  
Conclusions 
 The primary purpose of this study was to examine the similarities and differences in 
neurocognitive and social cognitive performance in a group of outpatients with schizophrenia 
and schizoaffective disorder in order to determine if they are more similar than they are distinct. 
Taken together, these results suggest no statistically significant differences on comprehensive 
neurocognitive measures between schizophrenia and schizoaffective disorder samples, and a 
difference favouring the schizoaffective disorder group on only one of the social cognition tasks.  
This difference, however, is insufficient in magnitude to provide objective validation for two 
distinct and separable psychotic syndromes. The findings of this study suggest that, with regard 
to deficits in cognition, considered a major aspect of psychotic spectrum disorders, schizophrenia 
and schizoaffective disorder demonstrate major overlap and are more similar than they are 
distinct. In terms of neurocognition, the current data and previous studies suggest that global 
cognitive impairment is a shared feature of schizophrenia and schizoaffective disorder. Findings 
are less clear when it comes to social cognition but in general suggest more similarities than 
differences. These results provide evidence consistent with the hypothesis that there is no natural 
distinction between cognitive functioning in schizophrenia and schizoaffective disorder. 
  As cognitive impairment is increasingly being understood as a core feature of psychotic 
disorders and an important factor that affects overall symptom course and functional outcome, 
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non-significant differences in cognition between schizophrenia and schizoaffective disorder 
furthers the idea that the two diagnostic categories are more similar than distinct. This cognitive 
homogeneity may reflect similar underpinnings for cognitive deficits in schizoaffective disorder 
and schizophrenia. Thus, these results support the research practice of pooling together 
schizophrenia and schizoaffective disorder groups of patients among shared genetics and 
neurobiological researchers. These findings, along with the majority of the literature reviewed, 
also question the validity and clinical utility of having a separate diagnostic category of 
schizoaffective disorder as distinct from schizophrenia. Nevertheless, schizoaffective disorder is 
clinically a frequent diagnosis. Until further studies are conducted to clarify its nosology, the 
clinical concept of a subgroup of psychotic patients with prominent affective symptoms remains 
important (e.g., Schumann et al., 2014). Thus, it is suggested that in the next version of the DSM 
the diagnostic category of schizoaffective disorder be removed and replaced with a more valid 
diagnosis of schizophrenia, mood specific.   
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Appendix 
Cognitive Domain MCCB Test Dependent Variables 
Processing Speed Category Fluency: Animal 
Naming 
Total number of animals named within 60-
seconds 
TMT: Part A  Time to correctly connect 25 numbered 
circles in ascending order 
BACS: Symbol Coding  Total number of correct symbol-number 
pairings completed within a 90-second time 
limit 
 
Working Memory WMS-III Spatial Span Sum of total number of correct trials 
demonstrated by tapping the correct sequence 
for the location of irregularly spaced blocks 
under forward and backward conditions from 
a 12-item list over three learning trials 
Letter-Number Span Total number of Letter-Number strings of 
increasing length correctly reordered  
\ 
Verbal Learning HVLT-R Total number of words recalled correctly 
from a 12-item list over three learning trials  
 
Visual Learning BVMT-R Total recall score for reproduction of six 
abstract figures over three learning trials  
 
Reasoning and problem 
solving 
NAB Mazes Total raw score based on time to complete 
seven mazes 
 
Attention/vigilance CPT-IP Mean d-prime value across 2-, 3-, and 4-digit 
conditions 
 
Note. TMT, Trail Making Test; BACS, Brief Assessment of Cognition in Schizophrenia; WMS-III, Wechsler 
Memory Scale-III; HVLT-R, Hopkins Verbal Learning Test Revised; BVMT-R, Brief Visuospatial Memory Test 
Revised; NAB, Neuropsychological Assessment Battery; CPT-IP, Continuous Performance Test - Identical Pairs.  
 
